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Pengyue Zhang 
STUDY DESIGNS AND STATISTICAL METHODS FOR PHARMACOGENOMICS 
AND DRUG INTERACTION STUDIES 
Adverse drug events (ADEs) are injuries resulting from drug-related medical 
interventions. ADEs can be either induced by a single drug or a drug-drug interaction (DDI). 
In order to prevent unnecessary ADEs, many regulatory agencies in public health maintain 
pharmacovigilance databases for detecting novel drug-ADE associations. However, 
pharmacovigilance databases usually contain a significant portion of false associations due 
to their nature structure (i.e. false drug-ADE associations caused by co-medications). 
Besides pharmacovigilance studies, the risks of ADEs can be minimized by understating 
their mechanisms, which include abnormal pharmacokinetics/pharmacodynamics due to 
genetic factors and synergistic effects between drugs. During the past decade, 
pharmacogenomics studies have successfully identified several predictive markers to 
reduce ADE risks. While, pharmacogenomics studies are usually limited by the sample 
size and budget.  
In this dissertation, we develop statistical methods for pharmacovigilance and 
pharmacogenomics studies. Firstly, we propose an empirical Bayes mixture model to 
identify significant drug-ADE associations. The proposed approach can be used for both 
signal generation and ranking. Following this approach, the portion of false associations 
from the detected signals can be well controlled. Secondly, we propose a mixture dose-
response model to investigate the functional relationship between increased dimensionality 
of drug combinations and the ADE risks. Moreover, this approach can be used to identify 
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high-dimensional drug combinations that are associated with escalated ADE risks at a 
significantly low local false discovery rates. Finally, we proposed a cost-efficient design 
for pharmacogenomics studies. In order to pursue a further cost-efficiency, the proposed 
design involves both DNA pooling and two-stage design approach. Compared to traditional 
design, the cost under the proposed design will be reduced dramatically with an acceptable 
compromise on statistical power. The proposed methods are examined by extensive 
simulation studies. Furthermore, the proposed methods to analyze pharmacovigilance 
databases are applied to the FDA’s Adverse Reporting System database and a local 
electronic medical record (EMR) database. For different scenarios of pharmacogenomics 
study, optimized designs to detect a functioning rare allele are given as well. 
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Chapter 1. Introduction 
Safety is always a primary concern for post-approval drugs that have already had 
their efficacy demonstrated (Lazarou et al., 1998). In the past decade, post-approval 
adverse drug effects (ADEs) were costing a $75 billion and causing more than 2 million 
injuries, hospitalizations and deaths per year (Hall et al., 2010). On one hand, ADEs can 
be caused by a single drug. Such causal relationships are discovered in premarketing 
clinical trials and updated through post-marketing surveillances. Consequently, significant 
findings will be documented on drug labels. On the other hand, ADEs can be caused by 
drug-drug interactions (DDIs). Currently, the knowledge bases for the mechanisms of DDIs 
are still under developing (Horn et al. 2007). Recent released statistics shown that DDIs in 
the United States alone associate with an estimated annual 195,000 hospitalizations and 
74,000 emergency room visits (Percha and Altman, 2013). As the usages of polypharmacy 
increase, researchers believed that DDIs will become a major threat to the public health in 
future (Hajjar et al., 2007).  
Many regulatory agencies of public health are now collecting data on ADEs 
reported by healthcare professionals, consumers, and manufacturers. Such databases are 
designed for post-approval drug safety surveillance and usually known as Spontaneous 
Reporting Systems (SRS) databases (Edwards, 1999). Preeminent SRS databases include 
the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System 
(FAERS), the World Health Organization’s (WHO) international pharmacovigilance 
program, and the Medicines and Healthcare Products Regulatory Agency’s (MHRA) 
Yellow Card Scheme. Besides SRS databases, electronical medical record (EMR) 
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databases constitute another valuable resource for pharmacovigilance (Wilke et al., 2011). 
Unlike SRS databases, EMR databases maintain longitudinal follow up on the patients’ 
medical histories. They usually contain precise temporal information on the occurrence of 
ADEs and usages of medications (Forster et al., 2008). Statistical models and data mining 
methods applied to the SRS and EMR databases have been recognized for their great values 
in detecting unknown drug- (DDI-) ADE associations (Szarfman et al., 2004).  
While SRS and EMR databases monitoring drug safety on a larger population scale, 
pharmacogenomics studies focus on explaining the individual heterogeneity on drug safety 
additional with drug efficacy with limited sample sizes. Such individual variabilities are 
considered to be significant challenges for current clinical practices (Ma and Lu, 2011). 
Pharmacogenomics studies address these challenges by testing associations between 
genetic markers and clinical outcomes. In past years, many genetic markers have been 
found to associate with different drugs’ responses by altering their distribution, metabolite, 
and excretion via pharmacogenomics studies (Phillips et al., 2001). Among different study 
designs, prospective cohort design is considered to be a golden standard to investigate drug 
response (Ross et al., 2012). Moreover, pharmacogenomics study may be based on 
different genotyping procedures, i.e. next generation sequencing (NGS) or single 
nucleotide polymorphism (SNP) array. 
Both pharmacovigilance studies via SRS or EMR databases and 
pharmacogenomics studies aim to minimize undesired ADEs. The knowledges gathered 
from these two approaches can be served as compliment to each other and finally benefits 
the public health (Wilke et al., 2011). For instance, a novel association detected from SRS 
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databases can be served as a primary outcome for a pharmacogenomics study. In returns, 
potential biomarkers can be identified and served as reference for making future 
prescriptions to avoid unnecessary ADEs. Either the analysis of pharmacovigilance 
databases or the study design of pharmacogenomics studies involves extensive and elegant 
statistical works. In this dissertation, we first propose a statistical model to detect single-
drug-ADE associations from FAERS database. Secondly, we investigate the functional 
relationship between increased dimensionality of DDIs and myopathy rates (a common 
ADE) by using a local EMR database. In the last, we develop a cost-efficient study design 
for pharmacogenomics studies. 
1.1.  Single-drug-ADE signal detection from pharmacovigilance database 
FAERS, a preeminent SRS databases, is designed to support the FDA's post-
marketing safety surveillance program for drug and therapeutic biologic products. FAERS 
database was updated quarterly a year and adopted MedDRA (Medical Dictionary for 
Regulatory Activities) preferred terms (PTs) as ADE names. An FAERS report contains 
on average four ADEs and four drugs. For any drug-ADE pair, those reports can be 
summarized into 2-by-2 contingency tables, in which contain the reports frequencies 
classified by the usage of the drug (yes/no) and the occurrence of the ADE (yes/no). Well 
known statistical methods to analyze SRS databases can be classified into frequentist, 
Bayesian or empirical Bayesian. 
Under empirical Bayesian approach, the hyper-parameters in the prior distribution 
will be estimated from the data via the observed likelihood. In 1999, DuMouchel (1999) 
proposed an empirical Bayesian mixture model (EBMM) and applied the model to FAERS 
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database. DuMouchel’s approach assumed that the report frequencies follow Poisson 
distributions and the prior distribution of relative risks (i.e., the means of report frequencies 
over their expectations under no association) is chosen to be a two-component mixture of 
gamma distribution. Statistics to measure drug-ADE associations are based on the posterior 
expectations of relative risks (RR) and are known as empirical Bayes geometric means 
(EBGMs). 
For Bayesian approach, the hyper-parameters in the prior distributions will not be 
estimated from data. In 1998, Bate et al. initially examined the WHO databases by 
assuming the report frequencies to follow binomial distributions and the prior distributions 
of the binomial probabilities were chosen to be uniform distributions and beta distribution. 
This approach are also known as the Bayesian confidence propagating neural network 
(BCPNN) and its  measurement for drug-ADE associations was named as information 
component (IC).  
Besides Bayesian and empirical Bayesian approaches, proportional reporting ratio 
(PRR) and reporting odds ratio (ROR) are two straightforward frequentist measurements 
for drug-ADE associations relying on the inference of 2 by 2 contingency tables (Evans et 
al., 2001 and van Puijenbroek et al., 2002). Another straightforward frequentist approach 
is to compare the report frequencies with their expectations under a Poisson assumption. 
Recently, Huang et al. (2011) proposed an inference method based on the likelihood ratio 
test (LRT). This approach simultaneously tests the associations between a drug with all 
ADEs or the association between an ADE with all drugs.  
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The major challenge for analyzing SRS databases is to control false positives from 
selected drug-ADE signals. Though LRT provides control on type one error rate, the null 
hypothesis dose not test any specific drug-ADE pair. Moreover, the theoretical distribution 
of LRT is not analytically derivable and the inference has to be based on extensive 
simulations. Bayesian false discover rate (BFDR) has been employed to control false 
positive rate on analyzing SRS databases by Ahmed et al. (2009). However, the BFDR is 
based on the magnitude of drug-ADE signals and may not suit for the nature of SRS 
reporting system. FAERS reports contain four drugs and ADEs on average. Besides of true 
signals, such a structure also generates a significant amount of background noises. For 
instance, strong drug-ADE associations yielded from co-medications. 
In this research, we assumed that drug-ADE associations can be classified into a 
zero risk group, a background noises group or an increased risk group. For a drug-ADE 
pair (drug_X and ADE_Y), zero association implies that drug_X is unrelated with ADE_Y 
and drug_X is not likely to be co-prescribed with any drug associated with ADE_Y. While, 
background noises are generated by either uncharacterized risk factors or confounding co-
medications. Finally, the drug-ADE associations belongs to the increased risk group are of 
interest. From this assumptions, we propose an EBMM together with an inference approach 
via conditional likelihood. The proposed method generates and ranks drug-ADE 
associations based on their posterior probabilities of belonging to background noises. 
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1.2.  The impact of increased dimensionality of drug interactions on ADEs’ risks 
Nowadays, many research and medical organizations maintains standard medical 
and clinical data from patients. In the state of Indiana, the Indiana Network for Patient Care 
(INPC) is a health information exchange data repository containing medical records of over 
15 million patients. The Common Data Model (CDM, Version 4) is a derivation of the 
INPC containing coded prescription medications, diagnoses, and observational data on 2.2 
million patients between 2004 and 2009. Like other EMR databases, CDM contains 
detailed temporal information on the occurrences of ADEs and usages of medications. Such 
information facilitates the application of advanced statistical modeling (i.e. longitudinal 
and time to event) techniques for pharmacovigilance studies. While traditional 
pharmacovigilance studies have focused on examining single-drug-ADE associations, 
recent studies have started to analyze the relation between DDIs and ADEs. 
DDIs involve complicated mechanisms including pharmaceutical DDIs, 
pharmacokinetics DDIs and pharmacodynamics DDIs (Han, 2015). Nowadays, DDI-
induced ADE became a major threat to public health, especially for elder patients (Juurlink 
et al., 2003). However, clinical investigations of DDIs are facing ethical issues (Conroy et 
al., 2000). Thus, knowledges gathered from pharmacovigilance databases are considered 
to be extremely valuable. The investigation of DDIs’ effect on ADEs can be based on either 
SRS databases or EMR databases. For instance, a pioneer analysis on INPC database 
identified that five drug pairs that significantly increased the risk of myopathy (a common 
muscle pathology) when compared to the expected additive myopathy risk from taking 
either of the drugs alone (Duke et al., 2012). Likewise, studies on FAERS database has 
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identified 171 novel drug pairs for eight ADEs (Tatonetti et al., 2012).   EMR databases 
keep records on the drug(s) a patient was taking while the patient experienced the ADE(s). 
As such information are usually unavailable in SRS databases, delicate analyses of EMR 
data will provide unique assets. For instance, an interesting example can be seen by Du et 
al., (2015) in which the temporal information were utilized to investigate the directional 
effect of high-order drug interactions on myopathy rates via a graphic mining approach. 
Currently, many of the mechanisms of DDIs are still remains unclear (Kiser et al., 
2012). Though the above mentioned studies are enlightening, the investigation of the 
relation between drug combinations and ADEs still facing two major challenges. As the 
dimensionality of drug interactions increases, the number of different drug combinations 
increases tremendously. Such a problem becomes the first obstacle on learning the relation 
between DDIs and ADEs. Current DDI studies merely examine the relations between two-
way or three-way DDIs and ADEs. False positive control is the second obstacle. For 
instance, there are about 2.7 × 1011 possible four-way drug combinations from the 1,600 
FDA proved drugs. An effective approach to control false positive rate for DDI detection 
from tremendous drug combinations is still under developing. 
In this research, we focus on investigating the functional relationship between 
increased dimensionality of drugs interactions and myopathy rates. Myopathy is a muscular 
disease and a common ADE. Acquired myopathy may due to many unrelated causes. For 
instance, it can be either induced by drug (DDI) or everyday items like alcohol (Preedy et 
al., 2001). Such a nature structure must be took account on exploring the relation between 
drug combinations and myopathy.  Thus, we assume that the myopathy risks under 
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different drug combinations will be either unchanged or escalated as the dimensionality of 
drug interactions increasing. Based on such an assumption, we propose a mixture dose-
response model and apply the proposed model to the INPC databases (Zhang et al, 2015). 
The nature structure of the proposed mixture model gives the posterior probability of a 
drug combination to have a constant risk. Hence, the drug combinations with increased 
myopathy risk can be detected. 
1.3.  Cost-efficient design for pharmacogenomics study  
Pharmacovigilance studies based on EMR or SRS databases are crucial for 
detecting novel drug-ADE associations, especially for rare and uncommon ADEs. Though 
pharmacovigilance studies have many advantages compared with small scaled studies, they 
do not reveal the mechanisms of drug-induced ADEs or DDIs. The toxicity of any drug 
involves its absorption, distribution, metabolism and excretion (ADME). For instance, 
reduced execration rate of a compound_X will yield into an over accumulation of X in 
human system. Hence, the concentration of X may exceed its maximum tolerated limit and 
result in toxicities. As the ADME of drugs in human system is predominantly carried out 
by the products (enzymes) of human genome, pharmacogenomics study is a powerful 
approach to learning drug response. During the past years, pharmacogenomics studies 
identified over a hundred genes or genetic markers to be associated with drug responses 
(Lee et al., 2014). Those valuable knowledges not only reveal the mechanisms for the 
findings from pharmacovigilance studies, but also can be served as guidance for future 
prescriptions to avoid unnecessary ADEs (Khoury et al., 2012).  
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Population based pharmacogenomics studies usually conduct by testing the 
associations between genetic markers and drug responses. Two major statistical 
approaches to test such associations include comparing minor allele frequencies (MAFs) 
of genetic markers between cases and controls for a dichotomized drug responses, and 
fitting regression models by using drug responses as dependent variable(s) and genetic 
markers as independent variables (Montana, 2006). For accurate genotyping, next 
generation sequencing (NGS) and SNP array are the most common procedures. SNP array 
can be used to examine genotype for pre-specified SNP markers (LaFramboise, 2009). It 
is a highly precise and economic approach. While, NGS sequences the target genome in a 
whole. Hence, NGS has the advantages on detecting rare mutations with relative large 
effects. Though the expenses of genotyping are keep on dropping, pharmacogenomics 
studies with relative large sample size are still costly (Sboner et al., 2011). 
During the past years, many researches have been focused on cost-efficient designs 
for different types of genetic association study. For case-control designs, genetic 
associations are usually tested by comparing the MAFs between the two groups. In real 
application, the estimated MAFs are the sufficient statistics (sample means). Such a feature 
motives researchers to estimate MAFs from pooled DNA samples (Sham et al., 2002). By 
decreasing the number of samples to be genotyped, DNA pooling now becomes a practical 
solution to reduce genotyping cost for both SNP array based or NGS based genetic 
association study. Though pooling of DNA may introduce extra variation on estimating 
MAFs, such variations can be minimized for careful designed experiments (Macgregor, 
2007).  
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For genetic association study using SNP array, two-stage design is another 
promising and practical approach to reach cost-efficiency. Two-stage designs for genetic 
association study are typically made up of a marker screening stage and a marker validation 
state (Skol et al. 2006). In the first stage of a two-stage design (marker screening), all 
markers will be tested only in a portion of samples. In the second stage (marker validation), 
markers with strong evidence of association will be further tested by using the remaining 
samples. If a marker is statistically significant in the second stage, a genetic association 
will be claimed.  
Both of the above mentioned approaches can greatly reduce the cost of genotyping 
with a little compromise on statistical power. In this research, we propose a two-stage 
design involving DNA polling to reach further cost-efficiency. In the first stage, the 
proposed design will identify promising markers by comparing MAFs that estimated from 
pooled DNA sequencing (Pooled-seq). Pooled-seq will enable the detection of functioning 
rare alleles (Vallania et al., 2012). After the calling of variants, promising markers will be 
further individually genotyped by SNP array in the second stage. Aiming for greater 
statistical power, the associations will be validated by regression models in stage two. In 
order to evaluate sample size and power, the joint distribution of the test statistics in stage 
one and two will be established by making parametric assumptions. Finally, optimal 
designs under different scenarios will be given. 
The remaining part of this dissertation is organized as follows. In chapter 2, we 
present a novel EBMM for detecting single-drug-ADE association. The proposed model 
will be applied to the FAERS database. Chapter 3 develops a mixture dose-response model 
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to investigate DDIs. The INPC data will be examined by the proposed method. In chapter 
4, we propose cost-efficient designs for pharmacogenomics studies. Chapter 5 concludes 
and discusses the proposed research.  
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Chapter 2. An Empirical Bayes Adverse Drug Event Signal Detection Algorithm 
and Its False Discovery Rate for the Adverse Event Reporting System 
Summary: Post-approval adverse drug events (ADEs) are a major global health concern. 
FDA’s Adverse Event Reporting System (FAERS) database has been recognized for its 
value in detecting significant drug-ADE associations. While current statistical methods 
rank signals by the magnitude of drug-ADE associations (e.g. relative risks), its 
background noises has not yet been adequately modeled, and the false discovery rate of the 
drug-ADE detection has not been investigated. We propose a three-component empirical 
Bayes mixture model based on the nature risk structure in the FAERS. In this model, a drug 
might not cause an ADE; or drug-ADE pairs with positive report frequencies are close to 
the background ADE risk; or some drug-ADE pairs have much higher ADE risks than the 
background risk. Under this model framework, the local false discovery rate (lFDR) can 
be estimated for each drug-ADE signal. FAERS data analysis and simulation results 
showed that lFDR top-ranked signals have better or equally good performance in selecting 
true drug-ADE associations comparing to existing methods. Most interestingly, we 
discover that lFDR top-ranked drug-ADE signals show a different pattern, hence is 
complementary to the other existing methods. 
2.1.  Introduction 
Drug safety surveillance has been the primary research for the post-approval drugs 
(Lazarou et al., 1998). Spontaneous Reporting Systems (SRS) collect data on adverse drug 
event (ADE) reports by healthcare professionals, consumers, and manufacturers. These 
databases provide a valuable source for post-approval drug safety surveillance. The U.S. 
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Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) is a 
prominent SRS database. It was designed to support the FDA's post-marketing safety 
surveillance program for drug and therapeutic biologic products, and it contains extensive 
information on ADEs and medication error reports. FAERS data analyses have been 
recognized for their great value in detecting unknown drug-ADE associations (Szarfman 
et al., 2004). 
When ADEs were reported into an SRS, the system was designed to capture all the 
medications and disease conditions. However, there is a great deal of uncertainty on which 
exact drugs that caused the ADEs. Therefore, reports unfortunately included many 
medications that might not be related to the ADEs. This is one mechanism that false 
positive drug-ADE signals were present in the SRS. For instance, the FAERS reports that 
have been used in our analysis contained four drugs and four ADEs on average. If an ADE 
is assumed to be caused by only one drug, a significant number of the observed drug-ADE 
pairs were expected to be false positives (Ali, 2011). Another source of false positive is the 
reporting error for both drugs and ADEs. Our initial FAERS data analysis revealed that 
there were greater than 300,000 distinctive drug names, while there are only less than 2,000 
FDA approved drugs. While our primary purpose is to identify the true drug-ADE signals 
from an SRS, the critical element for a data analysis is that how it differentiates the true 
signals from the false positive signals (Wang et al., 2014). 
Reports for a drug-ADE pair is usually summarized by a 2-by-2 contingency table 
from the SRS database. Such table contains the report frequencies classified by the usage 
of a drug (yes/no) and the occurrence of an ADE (yes/no). The statistics of interest are the 
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report frequency of this drug-ADE pair (outcome) and its expectation under the no 
association assumption. In other words, the expected frequencies under no association 
assumption mean the average false positive report frequencies. We also refer this false 
positive frequencies as the background distribution of a drug-ADE pair’s observed 
frequency in our later derivation. By considering the observed relative risk (RR) as the 
ratio of report frequency over its expectation, a class of methods for the SRS data analysis 
have been developed. These methods are also known as disproportionality analyses (DPAs), 
as their statistics to quantify drug-ADE associations are based the variants of observed RR. 
The proportional reporting ratio (PRR) proposed by Evans et al., (2001) and the likelihood 
ratio test (LRT) proposed by Huang et al., (2011) etc. are frequentist DPAs. Their 
inferences rely on the both magnitude of the observed RRs and p-values.  
While, Information components (IC) is Bayesian DPA and EBGM is empirical 
Bayesian DPA (Bate et al., 1998 and DuMouchel, 1999). For instance, EBGM refers to the 
empirical Bayesian geometric mean of a drug-ADE pair’s RR (DuMouchel, 1999). Under 
this approach, a two-component mixture of gamma distributions was used as prior 
distribution for the RRs and the report frequencies themselves were assumed to follow 
Poisson distributions. Implementing Bayesian DPAs, their signal detection thresholds are 
based on either posterior expectations of RRs or posterior probabilities (Ahmed et al., 
2009). Generally, DPAs do not require complicated modeling; are computational efficient; 
and can be applied to multiple ADEs or FAERS as a whole (Harpaz et al., 2013).  
Currently, DPA methods focus on the magnitude of the RRs (or the RRs adjusted 
by sample sizes) and the false positive signals in SRS databases have not been explicitly 
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modeled. In this paper, we however, speculate more explicit distributions of drug-ADE 
pairs’ RRs. We assume that a drug might not cause an ADE at all. This is based on the 
observation that 90% of drug-ADE pairs have 0 report frequency or observed RR. Secondly, 
we assume that many drug-ADE pairs with positive report frequencies are false positives. 
These are due to either the non-specific co-medications, or reporting errors. We consider 
these false positive drug-ADE pairs to have a background RR. Thirdly, some drug-ADE 
pairs have much increased RRs than the background RR. Therefore, we propose an 
empirical Bayes mixture model (EBMM) to characterize these three scenarios. Because 
one mixture distribution characterizes the null hypothesis, i.e. equally distributed drug-
ADE frequencies to the background ADE signals, we are able to estimate the false 
discovery rate in mining drug-ADE pairs with increased association. 
2.2.  Methods 
2.2.1.  Notations 
For 𝐼 drugs and 𝐽 adverse drug events (ADEs), the observed outcome 𝑁𝑖𝑗  is the 
report frequencies involving both drug 𝑖  and ADE 𝑗  (1 ≤ 𝑖 ≤ 𝐼, 1 ≤ 𝑗 ≤ 𝐽). Let 𝑁𝑖+ =
∑ 𝑁𝑖𝑗𝑗  be the marginal summation of all report frequencies involving drug 𝑖 and 𝑁+𝑗 =
∑ 𝑁𝑖𝑗𝑖  be the marginal summation of all report frequencies involving ADE 𝑗. The overall 
summation of report frequencies is 𝑁++ = ∑ ∑ 𝑁𝑖𝑗𝑗𝑖 . For a specific drug-ADE pair, its 
report frequency and the summations can be summarized into the following 2-by-2 
contingency table. 
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Table 2.1. Report frequency and the Summations 
 
With 
ADE 𝑗 
 
Without 
ADE 𝑗 
 
Summation 
With drug 𝑖 𝑁𝑖𝑗 𝑁𝑖+ − 𝑁𝑖𝑗 𝑁𝑖+ 
Without Drug 𝑖 𝑁+𝑗 − 𝑁𝑖𝑗 
𝑁++ − 𝑁+𝑗
− 𝑁𝑖+ + 𝑁𝑖𝑗 
𝑁++ − 𝑁𝑖+ 
Summation 𝑁+𝑗 𝑁++ − 𝑁+𝑗 𝑁++ 
 
Based on table 2.1, under no drug-ADE association (null), all drugs should have a 
similar risks to ADE 𝑗, which can be estimated as 
𝑁+𝑗
𝑁++
. Thus, we assume the expectation of 
𝑁𝑖𝑗  under the null is 𝐸𝑖𝑗 =
𝑁+𝑗
𝑁++
× 𝑁𝑖+. For the compliment of 𝑁𝑖𝑗 , 𝑁𝑖𝑗
− = 𝑁+𝑗 − 𝑁𝑖𝑗 , We 
define its expectation as 𝐸𝑖𝑗
− =
𝑁+𝑗
𝑁++
× (𝑁++ − 𝑁𝑖+). 
2.2.2.  A review on DPA methods 
2.2.2.1.  PRR and ROR  
The PRR refers to proportional reporting ratio (Evans et al., 2001). It is defined as 
PRR𝑖𝑗 =
𝑁𝑖𝑗 𝑁𝑖+ ⁄
(𝑁+𝑗−𝑁𝑖𝑗) (𝑁++−𝑁𝑖+)⁄
=
𝑁𝑖𝑗 𝐸𝑖𝑗 ⁄
(𝑁+𝑗−𝑁𝑖𝑗) 𝐸𝑖𝑗
−⁄
. 
Thus PRR can be considered as the observed relative risks (RRs). Similarly, the reporting 
odds ratio (ROR) is defined as (van Puijenbroek et al., 2002): 
ROR𝑖𝑗 =
𝑁𝑖𝑗 (𝑁𝑖+ − 𝑁𝑖𝑗) ⁄
(𝑁+𝑗 − 𝑁𝑖𝑗) (𝑁++ − 𝑁+𝑗 − 𝑁𝑖+ + 𝑁𝑖𝑗)⁄
. 
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These methods are standard approaches for analyzing 2-by-2 contingency tables. Normal 
approximation can be used to compute the variances for PRR and ROR. Some literatures 
suggested (e.g., Hauben and Aronon 2009) to use 1 as signal detection threshold for the 
lower bond of PRR/ROR’s 95% confidence.  
2.2.2.2.  Likelihood Ratio Test (LRT) 
The LRT is a frequentist approach, in which the report frequencies 𝑁𝑖𝑗  and its 
compliment 𝑁𝑖𝑗
− = 𝑁+𝑗 − 𝑁𝑖𝑗  are assumed to follow Poisson distributions such that 
𝑁𝑖𝑗~Pois(𝑁𝑖+ × 𝑝𝑖𝑗) and (𝑁+𝑗 − 𝑁𝑖𝑗)~Pois([𝑁++ − 𝑁𝑖+] × 𝑝𝑖𝑗
−). For a selected ADE 𝑗, 
the null hypothesis was 𝐻0: 𝑝𝑖𝑗 = 𝑝𝑖𝑗
− , 1 ≤ 𝑖 ≤ 𝐼 and alternative hypothesis was 𝐻1 = ¬𝐻0. 
Hence, LRT tests the association either between an ADE and all drugs or a drug and all 
ADEs. Plugging in the MLEs for 𝑝𝑖𝑗s and 𝑝𝑖𝑗
−s, the log-likelihood ratio (llr) for drug 𝑖 and 
ADE 𝑗 was given by: 
llr𝑖𝑗 = 𝑁𝑖𝑗 log(𝑁𝑖𝑗 𝐸𝑖𝑗  ⁄ ) + (𝑁+𝑗 − 𝑁𝑖𝑗) log[(𝑁+𝑗 − 𝑁𝑖𝑗) 𝐸𝑖𝑗
−⁄ ] (2.1) 
For an ADE 𝑗, the statistic to test hypothesis takes the maximum of llr𝑖𝑗 over 𝑖 (i.e. drugs), 
such that MLR𝑗 = max𝑖(llr𝑖𝑗). The exact distribution of MLR𝑗 is not analytically derivable 
and the p-value for testing the null hypothesis 𝐻0: 𝑝𝑖𝑗 = 𝑝𝑖𝑗
− , 1 ≤ 𝑖 ≤ 𝐼 had to be obtained 
through extensive simulations. In order to obtain the p-value, Huang et al. (2011) assumed 
the outcomes to follow a multinomial distribution as 𝑁𝑖𝑗~𝑀𝑁(𝑁+𝑗, 𝑷) under the null, 
where the 𝑷 is a vector of 𝐼  elements with 𝑃𝑖 =
𝑁𝑖+
𝑁++
. In Huang et al. (2011), the 95th 
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percentile of the simulated MLRs under the null were suggested as the threshold to test 
hypothesis and generate signals.  
2.2.2.3.  Information component (IC)  
IC was proposed by Bate et al. (1998) via Bayesian confidence propagation neural 
network (BCPNN). This approach assumed that 𝑁𝑖𝑗s, 𝑁𝑖+s and 𝑁+𝑗s following binomial 
distributions. The prior distribution of the probability parameters were chosen to be beta 
and uniform distributions. The model are shown as follow: 
𝑁𝑖𝑗~Bin(𝑁++, 𝑝𝑖𝑗) and 𝑝𝑖𝑗~Beta [1, ( 𝑝𝑖+ × 𝑝+𝑗)
−1
]; 
𝑁𝑖+~Bin(𝑁++, 𝑝𝑖+) and 𝑝𝑖+~Uniform(0,1); and 
𝑁+𝑗~Bin(𝑁++, 𝑝+𝑗) and 𝑝+𝑗~Uniform(0,1). 
The BCPNN is a Bayesian approach and the hyper-parameters will not be estimated from 
data. Later, Noren et al. (2006) introduced a joint Dirichelet distribution as the prior and 
extended Bate et al.’s BCPNN model on accounting the dependence between  𝑝𝑖𝑗, 𝑝𝑖+ and 
𝑝+𝑗. Defined as IC𝑖𝑗 = log2 (
𝑝𝑖𝑗
𝑝𝑖+𝑝+𝑗
), IC is a measurement of disproportionality between 
the report frequency of a drug-ADE pair and its expectation. Its posterior expectation was 
(Van Puijenbroek et al., 2002), 
𝐸(IC𝑖𝑗) = log2 [
(𝑁𝑖𝑗+1)(𝑁+++2)
2
(𝑁+++2)2+𝑁++(1+𝑁𝑖+)(1+𝑁+𝑗)
]. (2.2) 
Using the delta method, the IC’s variance can be obtained as 
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𝑉(𝐼𝐶𝑖𝑗) =
1
(log 2)2
[𝐴 + 𝐵 + 𝐶], 
Where 
𝐴 =
𝑁++ − 𝑁𝑖𝑗 +
(𝑁++ + 2)
2
(𝑁𝑖+ + 1)(𝑁+𝑗 + 1)
− 1
(𝑁𝑖𝑗 + 1) [𝑁++ +
(𝑁++ + 2)2
(𝑁𝑖+ + 1)(𝑁+𝑗 + 1)
+ 1]
, 
𝐵 =
𝑁++ − 𝑁𝑖+ − 1
(𝑁𝑖+ + 1)[𝑁++ + 3]
 , 
𝐶 =
𝑁++ − 𝑁+𝑗 − 1
(𝑁+𝑗 + 1)[𝑁++ + 3]
 . 
After a normal approximation, the 2.5% quantile of IC’s posterior distribution (IC025) is 
computed as 𝐸(IC𝑖𝑗) − 1.96 × √𝑉(IC𝑖𝑗). The signal generation rule suggested by Bate et 
al. (1998) is IC025>0. 
2.2.2.4.  Empirical Bayesian geometric mean (EBGM) 
EBGM was proposed by DuMouchel (1999). This approach assumed 
𝑁𝑖𝑗~𝑃𝑜𝑖𝑠(𝜇𝑖𝑗) . Further, the relative risk (RR) was defined as 𝜆𝑖𝑗 =
𝜇𝑖𝑗
𝐸𝑖𝑗
 (observed RR, ?̂?𝑖𝑗 =
𝑁𝑖𝑗
𝐸𝑖𝑗
) . A two-component mixture of gamma distributions was 
chosen as prior distribution of RR: 
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𝜆𝑖𝑗~𝑃Γ(𝜆𝑖𝑗; 𝛼1, 𝛽1) + (1 − 𝑃)Γ(𝜆𝑖𝑗; 𝛼2, 𝛽2),  
where Γ(𝜆; 𝛼, 𝛽) =
𝛽𝛼
𝛤(𝛼)
𝜆𝛼−1 exp(−𝛽𝜆). 
(2.3) 
Following the conjugate relationship between Poisson distribution and gamma distribution, 
observed data follow a mixture of negative binomial distributions. The parameters in (2.3) 
can then be obtained by maximizing the observed likelihood. Empirical Bayes geometric 
mean (EBGM), a variant of posterior expectation of the RR, is an estimate of relative risk. 
EBGM𝑖𝑗 = 2
[𝐸(log 𝜆𝑖𝑗|𝑁𝑖𝑗, 𝐸𝑖𝑗)/ log2]. (2.4) 
This approach is also known as gamma Poisson shrinker (GPS), as it shrinks a drug-ADE 
pair’s observed RR, especially for a drug-ADE pair with small 𝑁𝑖𝑗, towards smaller values 
(Appendix figure A.4). The signal detection can be based on the 5% lower quantile of RR’s 
posterior distribution (EB05) (Levine et al., 2006). 
2.2.2.5.  Bayesian False Discovery Rate (BFDR)  
BFDR is calculated based on the posterior probability of null hypothesis. (Ahmed 
et al., 2009 and Ahmed et al., 2010). For DuMouchel’s EBGM, the BFDR of 𝜆𝑖𝑗 greater 
than a specific threshold 𝜆𝑡ℎ𝑟𝑒𝑠 was given by: 
𝑣𝑖𝑗(𝜆𝑡ℎ𝑟𝑒𝑠) = 𝑃(𝜆𝑖𝑗 > 𝜆𝑡ℎ𝑟𝑒𝑠|𝑁𝑖𝑗, 𝐸𝑖𝑗). (2.5) 
Different thresholds can be applied, for instance, generating signals by 𝑣𝑖𝑗(𝜆𝑡ℎ𝑟𝑒𝑠 = 2) >
1 − 0.05 is equivalent to EB05>2. 
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2.2.3.  Three-Component EBMM and Local False Discovery Rate 
This is our proposed method. The expectation 𝐸𝑖𝑗s, the RR 𝜆𝑖𝑗s and the observed 
RR ?̂?𝑖𝑗 are defined the same as in section 2.1 and 2.2.4. In the FAERS dataset, 90% of 
?̂?𝑖𝑗 = 0. Such a phenomenon was also observed by DuMouchel (1999) in which 71% of 
?̂?𝑖𝑗 = 0. Moreover, we assume the drug-ADE pairs on an FAERS reports can be classified 
as either signals or noises. The noises are induced by co-medications or correlations 
between ADEs. Hence, we assume that the RR follows a three-component mixture 
distribution: 
𝜆𝑖𝑗~𝑃1{𝐼(𝜆𝑖𝑗 = 0)} + ∑[𝑃𝑙Γ(𝜆𝑖𝑗; 𝛼𝑙 , 𝛽𝑙)]
3
𝑙=2
; 
𝛼2 = 𝛽2,  𝛼3 > 𝛽3 and 𝑃1 + 𝑃2 + 𝑃3 = 1. 
(2.6) 
In model (2.6), the first component, the point mass at 0, describes the drugs with 0 ADE 
frequencies. In the second component, the assumption 𝛼2 = 𝛽2, restricts the mean of RR 
equal to one. It describes the drug-ADE risk close to the background drug-ADE risk. This 
component serves as a “null distribution” in our later local false discover rate (lFDR) 
estimation. The third component characterizes the drug-ADR risk higher than the 
background risk. Drug-ADE pairs with their RRs belonging to the second or third 
component have their outcome 𝑁𝑖𝑗s following Poisson distribution with mean 𝜇𝑖𝑗 = 𝜆𝑖𝑗 ×
𝐸𝑖𝑗 . Drug-ADE pairs with their RRs belonging to the first component will have their 
outcome 𝑁𝑖𝑗s following an identity distribution with all mass at 0.  
 22 
 
If a drug-ADE pair’s RR belongs to component 2 and 3 in (2.6), the observed distribution 
for its report frequency can be derived by using the conjugate relationship between the 
gamma and Poisson distribution. By integrating out the latent 𝜆𝑖𝑗  [equation (2.7)], 𝑁𝑖𝑗 
follows a negative binomial distribution [equation (2.8)].  
 𝐹(𝑁𝑖𝑗; 𝛼𝑙 , 𝛽𝑙, 𝐸𝑖𝑗) = ∫Pois(𝑁𝑖𝑗|𝜆𝑖𝑗, 𝐸𝑖𝑗)Γ(𝜆𝑖𝑗; 𝛼2, 𝛽2)𝑑𝜆𝑖𝑗. (2.7) 
 
 𝐹(𝑁𝑖𝑗; 𝛼𝑙, 𝛽𝑙, 𝐸𝑖𝑗) =
Γ(𝑁𝑖𝑗 + 𝛼𝑙) × 𝐸𝑖𝑗
𝑁𝑖𝑗 × 𝛽𝑙
𝛼𝑙
𝛤(𝛼𝑙) × 𝑁𝑖𝑗! × [𝐸𝑖𝑗 + 𝛽𝑙]
𝑁𝑖𝑗+𝛼𝑙
. (2.8) 
Hence, the observed distribution function of 𝑁𝑖𝑗 based on our three-component EBMM is 
𝑃(𝑁𝑖𝑗) = 𝑃1𝐼(𝑁𝑖𝑗 = 0) + ∑[𝑃𝑙𝐹(𝑁𝑖𝑗; 𝛼𝑙 , 𝛽𝑙, 𝐸𝑖𝑗)]
3
𝑙=2
; 
𝛼2 = 𝛽2,  𝛼3 > 𝛽3 and 𝑃1 + 𝑃2 + 𝑃3 = 1. 
(2.9) 
Where in (2.9), 𝐹(𝑁𝑖𝑗; 𝛼𝑙 , 𝛽𝑙, 𝐸𝑖𝑗) is the negative binomial distribution function as shown 
in (2.8). The log-likelihood function based on (2.9) is 
𝑙𝑙(𝑵𝒊𝒋; 𝑬𝒊𝒋, {𝛼2 = 𝛽2, 𝛼3, 𝛽3, 𝑃1, 𝑃2}) = ∑∑log𝑃(𝑁𝑖𝑗)
𝑗𝑖
;  
𝑃3 = 1 − 𝑃1 − 𝑃2 
(2.10) 
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If we focus only on the drug-ADE pairs with positive counts, 𝑁𝑖𝑗 can be modeled via a 
conditional distribution. Under (2.9), the probability for a drug-ADE pair to have a zero 
report frequency is  
𝑃(𝑁𝑖𝑗 = 0) = 𝑃1 + (
𝛽2
𝐸𝑖𝑗 + 𝛽2
)
𝛼2
+ (
𝛽3
𝐸𝑖𝑗 + 𝛽3
)
𝛼3
; 
and the probability to observe a positive report frequency is 𝑃(𝑁𝑖𝑗 > 0) = 1 − 𝑃(𝑁𝑖𝑗 = 0). 
Hence, the conditional distribution for drug-ADE pairs with positive report frequencies is  
𝑃(𝑁𝑖𝑗 = 𝑘|𝑁𝑖𝑗 > 0)
=
𝐹(𝑘; 𝛼2,  𝛽2, 𝐸𝑖𝑗) +
𝑃3
𝑃2
× 𝐹(𝑘; 𝛼3,  𝛽3, 𝐸𝑖𝑗)
𝑃(𝑁𝑖𝑗 > 0; 𝛼2,  𝛽2, 𝐸𝑖𝑗) +
𝑃3
𝑃2
× 𝑃(𝑁𝑖𝑗 > 0; 𝛼3,  𝛽3, 𝐸𝑖𝑗)
. 
(2.11) 
In (2.11), the parameter 𝑟 = 𝑃3 𝑃2⁄  is considered as a single parameter in the estimation. 
Consequently, the final model has 4 parameters {𝛼2 = 𝛽2, 𝛼3, 𝛽3, 𝑟 = 𝑃3 𝑃2⁄  } . The 
conditional log-likelihood function for the observed data is written in (2.12). 
𝑙𝑙(𝑵𝒊𝒋; 𝑬𝒊𝒋, {𝛼2 = 𝛽2, 𝛼3, 𝛽3, 𝑟}) = ∑∑log[𝑃(𝑁𝑖𝑗 = 𝑘| 𝑁𝑖𝑗 > 0)]
𝑗𝑖
. (2.12) 
The lFDR for a drug-ADE pair is defined in (2.13). It represents the posterior probability 
that a drug-ADE pair’s RR belongs to the null distribution. 
lFDR(𝑁𝑖𝑗) =
𝑃2 × 𝐹(𝑁𝑖𝑗; 𝛼2, 𝛽2, 𝐸𝑖𝑗)
𝑃1 × 𝐼(𝑁𝑖𝑗 = 0) + ∑ [𝐹(𝑁𝑖𝑗; 𝛼𝑙 , 𝛽𝑙, 𝐸𝑖𝑗) × 𝑃𝑙]
3
𝑙=2
 (2.13) 
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In addition, for those drug-ADE pairs with positive counts, their lFDRs can be computed 
as:  
lFDR(𝑁𝑖𝑗 = 𝑘|𝑁𝑖𝑗 > 0) =
𝐹(𝑘; 𝛼2,  𝛽2, 𝐸𝑖𝑗)
𝐹(𝑘; 𝛼2,  𝛽2, 𝐸𝑖𝑗) +
𝑃3
𝑃2
× 𝐹(𝑘; 𝛼3,  𝛽3, 𝐸𝑖𝑗)
 (2.14) 
2.2.4.  Particle swarm optimization 
Particles swarm optimization (PSO), a global optimization technique, is used to 
maximize the log-likelihood (2.10) and the conditional log-likelihood (2.12) (Kennedy and 
Eberhart, 1995). In order to maximize the log-likelihood (2.10), particles (𝑿 =
{𝛼2 = 𝛽2, 𝛼3, 𝛽3, 𝑃1, 𝑃2})  is a 5-dimensional vectors. While the particles (𝑿 = {𝛼2 =
 𝛽2, 𝛼3, 𝛽3, 𝑟})is a 4-dimenional vectors for optimizing the conditional log-likelihood (2.12). 
Suppose 𝑇 particles are employed. In step 𝑆, the local best for the 𝑡th particle (𝑡 = 1,… , 𝑇) 
is defined to be 𝑳𝑡 = arg max
𝑿𝑡
𝑠 𝑠=1,…,𝑆
𝑙𝑙(𝑵𝒊𝒋; 𝑬𝒊𝒋, 𝑿𝑡
𝑠  ),   and the global best is defined as 𝑮 =
arg max
𝑳𝑡 𝑡=1,…,𝑇
𝑙𝑙(𝑵𝒊𝒋; 𝑬𝒊𝒋, 𝑳𝑡 ).  
The PSO was carried out by initializing the particle’s positions first. Before the 
maximum iteration or minimum error criteria is achieved, in each iteration, 𝑳𝑡 and 𝑮 are 
determined and the particles velocities (𝑽) and positions (X) are updated accord to (2.15).  
𝑽𝑡
𝑠 = 𝑤𝑠𝑽𝑡
𝑠−1 + 𝑈(0,1)𝐶1(𝑳𝑡
𝑠−1 − 𝑿𝑡
𝑠−1) + 
𝑈(0,1)𝐶2(𝑮
𝑠−1 − 𝑿𝑡
𝑠−1) and 𝑿𝑡
𝑠 = 𝑿𝑡
𝑠−1 + 𝑽𝑡
𝑠. 
(2.15) 
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In (2.15), the weight 𝑤𝑠  is set to be 𝑤𝑠 = (𝑤𝑚𝑎𝑥 − 𝑤𝑚𝑖𝑛) ×
(𝑖𝑡𝑒𝑟𝑚𝑎𝑥−𝑖𝑡𝑒𝑟)
𝑖𝑡𝑒𝑟𝑚𝑎𝑥
+ 𝑤𝑚𝑖𝑛 
according to Chaturvedi (2008) and 𝑈(0,1) is a random number between 0 and 1.  
2.2.5.  FAERS Data Processing  
FAERS database is updated quarterly and adopted MedDRA (Medical Dictionary 
for Regulatory Activities) preferred terms (PTs) as ADE names. Reports in the FAERS 
database, from 2004Q1 to 2012Q3, were selected for analysis. Among duplicated reports 
identified by the report primary IDs, only the latest reports were kept. From these 4,280,322 
processed reports, we further identified 356,734 drug names, and they were normalized by 
drug bank IDs. For those drug names failed to be covered by the drug bank IDs, 568 names 
with at least 1,000 reports were manually checked and corrected. For instance, drug name 
“Metformin HCL” was corrected to be Metformin. The final dataset includes 1,753 generic 
drug names and 15,445 ADE names (𝐼 = 1,753, 𝐽 = 15,445). Moreover, drugs labeled as 
the indications were removed before data analysis. This is our attempt to remove the 
contraindications bias between drugs and ADEs. 
We also select a subset of ADEs for further data analysis and simulation studies. 
These four ADE categories are: skin pigmentation disorder, myopathy, neuropathy and 
delirium; which contain 91 PT names. It is named as four-ADE data through the this article 
(𝐼 = 1753, 𝐽 = 91). Marginal and overall summations calculated from this four ADE 
dataset are denoted by 𝑁𝑖+
∗ , 𝑁+𝐽
∗ and 𝑁++
∗ . Details about this four-ADE data set can be found 
in the Appendix A. 
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2.2.6.  Drug-ADE signal validation 
SIDER (Side Effect Resource, http://sideeffects.embl.de/) contains the structural 
drug-ADE data curated from the drug labels. We used it to validate top-ranking drug-ADE 
associations, which are generated with various DPA methods. To normalize the drug names 
between FAERS and SIDER, our drug name dictionary (Wu et al., 2013), was implemented. 
2.3. FAERS Data Analysis 
2.3.1.  Overall Analysis of FAERS  
The full FAERS data were fitted into our proposed EBMM. In the data analysis, 
both the full log-likelihood model (2.10) and the conditional log-likelihood model (2.12) 
were optimized by PSO. The PSO reveals that the full log-likelihood EBMM failed to 
converge. It suggested that first mixture component, i.e. the point mass at 0, is not 
identifiable form the second and third components. Figure 2.1 shown that the maximum 
log-likelihood is not concave with respect to 𝑃1 and 𝑃2. On the other hand, the conditional 
likelihood EBMM, (2.12), had the converged parameters 
{?̂?2 = ?̂?2 =  1.6, ?̂?3 = 0.12, ?̂?3 = 0.03,  ?̂? = 0.23}. 
The contour plot for the conditional log-likelihood with respect to other parameters can be 
found in figure 2.2. Based on the MLEs of (2.12), the second component of RR had a mean 
equal to 1 and the third component of RR had a mean equal to 4. For drug-ADE pairs with 
a positive outcome, about 23% had their RRs belonging to the third component.  
 27 
 
 
Figure 2.1. Contour plot for the log-likelihood (2.10) with respect to 𝑃1 and 𝑃2 
  
 28 
 
  
  
 
 
Figure 2.2. Contour plot for the conditional log-likelihood (2.12) with respect to 
different parameters 
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We also fitted the GPS model reviewed in section 2.2.2.4 (DuMouchel, 1999), 
whose parameters are 
{?̂?1 = 0.99, ?̂?1 =  1.30, ?̂?2 = 0.11, ?̂?2 = 0.03,  ?̂? = 0.86} 
Under DuMouchel’s model, the drug-ADE pairs to have an expected RR either equals to 
0.76 or 3.67. Thus, the proposed model and DuMouchel’s model shown a similar pattern 
for drugs with increased RRs. Thus, the second component of the GPS model (mean=3.67) 
has a closed shape with the third component of the proposed model (2.6). While, the first 
component of the GPS model (mean=0.69) represents a mixture of the first and second 
component of model (2.6). Under the GPS model, 14% drug-ADE pairs are considered to 
have increased RRs. 
2.3.2.  Four-ADE Data Analysis 
A conditional EBMM was fitted to this four-ADE data set, and the parameter 
estimates in (2.12) are 
{?̂?2 = ?̂?2 =  1.86, ?̂?3 = 0.38, ?̂?3 = 0.072,  ?̂? = 0.21}. 
Thus, the second component of RR had a mean equal to 
?̂?2
?̂?2
=1 and the third component of 
RR had a mean of  
?̂?3
?̂?3
= 5.32. For drug-ADE pairs with a positive outcome, about 21% had 
their RRs belonging to the third component. A density plot for the back ground risk and 
increased risk together with their mixtures are shown in appendix figure A.5. While the 
histogram of estimated lFDRs are shown in appendix figure A.6. 
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In order to compare the performances of various DPA methods, top ranked drug-
ADE signals were generated by different approaches. Since LRT is highly computationally 
expensive, it is infeasible to simulate its small p-values for drug-ADEs associations. Hence, 
we only exam the likelihood ratio based ranking for the LRT method, which shall be 
consistent with p-value rankings. We also observed top-20 ranked signals by each methods 
to have different features on the magnitude of outcome and observed RR (Figure 2.3). 
lFDR top ranked signals have a moderate magnitude of sample size and greater observed 
RR. For details on the performance of signal generation/ranking by each method, please 
visit Appendix A. 
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Figure 2.3. The report frequencies and the observed RRs for top-20 ranked 
signals by different methods. 
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We further validated the top-20 ranked signals by EBGM, BFDR, PRR, LRT, IC 
and lFDR in SIDER. Six out of BFDR top-20 ranked signals and nine out of LRT top-20 
ranked signals are documented in SIDER (5 overlaps). The average outcome of these 
associations is comparably larger than the top-20 ranked singles by other methods, while 
the observed RR is moderate. Seven out of IC and six out of lFDR top-20 ranked signals 
are documented in SIDER (6 overlaps). These signals have a moderate average outcome 
with higher observed RRs. Three out of EBGM top-20 ranked signals are documented in 
SIDER. Finally, only one PRR top-20 ranked signals is documented in SIDER. One SIDER 
documented associations is ranked within top 20 by all 5 methods except PRR. It is 
sildenafil and optic ischemic neuropathy (𝑁𝑖𝑗 = 713, 𝐸𝑖𝑗 = 8.06). Details of top-20 ranked 
associations by each methods are in Appendix A.  
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2.4.  Simulation studies 
2.4.1.  Simulation Study 1: A Mixture Model Based Data Simulation and Analysis 
We use the data structure in the four-ADE data set as the simulation framework. 
Among these 1753×91 drug-ADE combinations, 40% RRs are assumed to be 0, 45% RRs 
follow a gamma distribution with mean of 1, and 15% RRs follow a gamma distribution 
with mean of 3.7. In particular, the data are simulated as follow: 
1. Generate 𝛿𝑖𝑗 = 1, 2 or 3 and 𝜆𝑖𝑗  from [0.4 × 𝐼(𝜆𝑖𝑗 = 0)]
𝐼(𝛿𝑖=1) × [0.45 ×
Γ(𝜆𝑖𝑗; 1.2, 1.2)]
𝐼(𝛿𝑖=2) × [0.15 × Γ(𝜆𝑖𝑗; 0.33, 0.09)]
𝐼(𝛿𝑖=3)
, where 𝛿𝑖𝑗  is a trinomial 
distribution with parameter (𝜋 = 0.4, 0.45 and 0.15).  
2. For each durg 𝑖 (1 ≤ 𝑖 ≤ 1753), a vector 𝑷𝑖 is obtained by 𝑃𝑖𝑗 =
𝑁+𝑗
∗ ×𝜆𝑖𝑗
𝑁++
∗  (for 𝑗 from 1 
to 91). 
3. Generate outcomes from the multinomial distribution (𝑁𝑖1, 𝑁𝑖2, … , 𝑁𝑖𝐽 )~𝑀𝑁(𝑁𝑖+
∗ , 𝑷𝑖). 
All the prescribed DPA methods were applied to the simulated data. For the 𝑘th 
ranked signal by a method, its 𝛿𝑖𝑗 value is denoted by 𝛿[𝑘], which indicates the component 
of the mixture distribution. 𝛿[𝑘] = 3 would suggest that the 𝑘th ranked signal comes from 
component 3 of the mixture distribution, whose ADE risk is higher than the background 
risk. The true positive rate (TPR) for top-𝐾 ranked signals is defined as 
TPR𝐾 = 𝐴𝑉𝐸 (
∑ 𝐼(𝛿[𝑘] = 3)
𝐾
𝑘=1
𝐾
). (2.14) 
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The top-20, 50, 100 and 200 ranked associations of positive outcomes by each methods 
were evaluated. Based on 1,000 simulations, results show that EBGM, IC and lFDR 
ranking provide better TPRs (Figure 2.4).  
 
Figure 2.4. TPR of top-200 ranked signals by each method 
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We also investigated each methods on their properties of signal ranking. Moreover, we 
evaluated the signals generated by the following rules EB05>2, IC025>0, PRR025>1 and 
lFDR<0.05 in terms of false discovery (portions of 𝛿𝑖𝑗 = 2 among signals). Results shown 
that lFDR<0.05 is the only rule controls the false discovery rate at 0.05, though it is a 
conservative approach, compared to other rules. For details, please go to Appendix A. 
2.4.2.  Simulation study 2: generate false drug-ADE signals through co-medications 
We select 40,000 random FAERS reports to generate simulated report frequencies 
for 20 hypothetical ADEs. From these 40,000 reports, 100 random drugs (frequencies range 
from 10 to 3391) are selected for simulation. We assume 5 drugs are causal to each ADE 
(Risk~Uiform[0.05,0.5]) and multiplicative risk is assumed for multiple causal drugs; and 
all the other drug-ADE associations are constructed through the co-medication data 
sampled from the FAERS. The data are generated as follow: 
1. Select 5 random drugs to be casual for each ADE. 
2. For the casual drugs, generate ADE risks from a uniform distribution U[0.05, 0.5].  
3. For each report, determine the ADE risks. If multiple casual drugs for an ADE appear 
in a report, the risk is assumed to be multiplicative. 
4. For each report, Generate the ADEs (Yes/No) by binary distributions with the 
associated ADE risks. 
The report frequencies for all drug-ADE pairs (100×20) were obtained and the DPA 
methods were applied. All DPA methods have an at least 90% of causal drugs among their 
top-20 and 50 ranked signals except PRR. We further compared simulated report 
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frequencies and their RRs for the top-20 ranked signals by each method. As Figure 2.5 
showed, their patterns are very similar to the Four-ADE Data Analysis (figure. 2.3). EBGM 
top ranked drug/ADE pairs tends to have very small frequencies; while BFDR and LLR 
top ranked drug/ADE pairs tend to have much bigger frequency. The top ranked drug/ADE 
pairs of our method, lFDR, on the other hand, has moderate sample size. 
 
Figure 2.5. The simulated report frequencies and the simulated observed RRs for top-
20 ranked signals by different methods. 
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2.4.3 Simulation Study 3: Examine the consistency of the lFDR estimates 
The consistency of the proposed lFDR were examined under both simulation study 1 and 
simulation study 2. For a drug-ADE pair, let 𝛿𝑖𝑗 = 1 if the drug has an increased risk (or 
causal) to the ADE and 0 otherwise. Let lFDR̂𝑖𝑗 be the estimated lFDR for this drug-ADE 
pair. Then we partition the simulated outcomes, [𝑁𝑖𝑗 𝐸𝑖𝑗 𝛿𝑖𝑗 lFDR̂𝑖𝑗]s, into intervals 
accord to their observed RRs. Within each partition, the model based FDR is defined as 
the average of lFDR̂𝑖𝑗s and the empirical FDR is defined as the average of 𝛿𝑖𝑗s. Under 
simulation study 1, the model based FDRs are shown to be consistent with empirical FDRs 
[figure 2.6 (A)]. While under simulation study 2, the model based FDRs are slightly diverge 
from empirical FDRs [figure 2.6 (B)]. 
A B 
  
Figure 2.6. (A) Comparison of model-based FDR and empirical FDR in simulation study 1. 
(B) Comparison of model-based FDR and empirical FDR in simulation study 2. 
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2.5.  Conclusion and Discussion 
In this article, an empirical Bayes model was proposed to characterize the risk 
structure of FAERS databases. Through defining the background risk (i.e. null), the local 
false discovery rate (lFDR) was formally introduced as a part of the mixture model. This 
mixture model and its lFDR measure the strength of drug-ADE signals for mining FAERS 
database. Simulation and analysis results showed that the top-ranked drug-ADE signals by 
lFDR have equally good and sometimes better performance in selecting true associations 
than the existing methods do. It also provides much needed false discovery rate estimation 
for top ranked drug-ADE signals. Interestingly, we further discover that the top-ranked 
drug-ADE signals selected from different methods show different patterns. The lFDR top 
ranked signals have moderate report frequencies (20~400) with relative high observed RRs 
(16~200). While EBGM’s top ranked signals have small report frequencies (10~50) and 
high observed RRs (50~400); and LLR and BFDR top rank signals have much bigger 
frequencies (200~5000) with much smaller RRs (2~15). These interesting suggests 
strongly recommended that top-ranked drug-ADE signals from different methods are 
complementary to each other. 
We want to point out that there is a fundamental difference between our mixture 
model based lFDR and the BFDR (Ahmed et al., 2009) In our model (2.6), condition on 
the positive report frequencies, the relative drug-ADE risk is a mixture of two Gamma 
distributions, one has a mean of 1 (i.e. null), and the other one has a mean larger than one 
(i.e. alternative). These two Gamma distributions are estimated from all the drug-ADE 
signals, and the lFDRs are estimated at the same time. This mixture model and its lFDR 
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framework follow the same theoretical structure as that proposed in Storey (2002). On the 
other hand, Ahmed’s BFDR (Ahmed et al., 2009) and its null/alterative definitions are 
totally different from the underlying statistical distribution of the drug-ADE signals. In 
their BFDR paper, the relative risks of drug-ADE pairs follow the EBGM model, which 
assumed to be a mixture of two Gamma distributions, one has a mean less than 1, and one 
has a mean larger than 1. In calculating the BFDR, a risk threshold is selected to define the 
null and the alternative, and BFDR is then calculated based on the EBGM model. The 
EBGM model has nothing to do with the null and alternative drug-ADE risks. Therefore, 
BFDR does not have a cohesive null/alternative risk assumption. However, Our lFDR 
approach has null/alternative statistics risk models, which are fully estimated from drug-
ADE data. Our mixture model of drug-ADE risk and its lFDR are cohesively specified and 
estimated. 
The consistency of our proposed lFDR estimations was investigated. When all the 
drug-ADE pairs totally independently follow our mixture model, the lFDR estimation is 
consistent. However, when there are correlations among drug-ADE pairs, lFDR is 
somehow under estimated. The correlations among drug/ADE in FAERS reports can come 
from different sources. For examples, the correlations can be generated form co-
medications; and the correlations can be generated from correlated ADE symptoms. 
Further investigation of correlated drug-ADE pairs is very much needed.  
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Chapter 3. A Mixture Dose-Response Model for Identifying High-Dimensional Drug 
Interaction Effects on Myopathy Using Electronic Medical Record Databases 
Summary: Interactions between multiple drugs may yield excessive risk of adverse effects. 
This increased risk is not uniform for all combinations, although some combinations may 
have constant adverse effect risks. We developed a statistical model using medical record 
data to identify drug combinations that induce myopathy risk. Such combinations are 
revealed using a novel mixture model, comprised of a constant risk model and a dose–
response risk model. The dose represents the number of drug combinations. Using an 
empirical Bayes estimation method, we successfully identified high-dimensional (two to 
six) drug combinations that are associated with excessive myopathy risk at significantly 
low local false-discovery rates. From the curve of a dose–response model and high-
dimensional drug interaction data, we observed that myopathy risk increases as the drug 
interaction dimension increases. This is the first time that such a dose–response relationship 
for high-dimensional drug interactions was observed and extracted from the medical record 
database. 
3.1.   Introduction 
Post-approval adverse drug effects (ADEs) are a major global health concern, 
costing a $75 billion per year and causing more than 2 million injuries, hospitalizations and 
deaths (Ahmad, 2003 & Lazarou et al., 1998). Drug-drug interactions (DDIs), a major 
cause of ADEs, thus represent a severe detriment to public health. Based on statistics 
released recently by the National Health Statistics Report and the results of pharmaco-
epidemiology studies, DDIs in the United States alone associate with an estimated annual 
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195,000 hospitalizations and 74,000 emergency room visits (Niska et al., 2010 & Becker 
et al., 2007). With increasing use of polypharmacy, the incidence of DDIs is very likely to 
increase in the coming years (Percha and Altman, 2013). 
Traditional pharmacovigilance studies have focused on associating single drugs 
with single ADEs (Ryan et al., 2012). Pioneering work by DuMouchel using an empirical 
Bayes (EB) method was a groundbreaking contribution to pharmacovigilance research 
(DuMouchel, 1999). More recent successful studies have significantly expanded the 
dimension of associations. For example, Duke and Li et al. (2012) investigated drug 
interactions, using a local medical records database at Indiana University to successfully 
identify multiple, novel drug interaction pairs that significantly increased myopathy risk 
above a mere additive risk from the two drugs taken alone. In another example of multiple 
drug-ADE discovery, Tatonetti and Altman et al. (2012) further expanded association 
analysis between drugs or drug interactions and adverse events to assess all drugs and 
ADEs. Using the FDA’s Adverse Event Reporting System (FAERS) as a training set, and 
Stanford’s electronic medical records as a validation set, they identified 47 associations of 
drugs and drug interaction effects. To detect associations between any combinations of 
drugs and any combinations of adverse events, they implemented an association rule 
mining approach based on the FAERS database, claiming that 67% of associations were 
clinically validated by domain experts (Harpaz et al., 2010). Moreover, the computational 
efficiency of association rule mining was recently further improved by Xiang and Li et al. 
(2014). 
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Despite the above-described successes, current computational methods for high-
dimensional drug interactions have their own intrinsic limitations, including the lack of a 
false positive control, and a lack of functional relationship between high-dimensional drug 
interactions and ADE frequency. To address these two concerns, in this study, we 
employed a novel approach, a mixture dose response model combined with an empirical 
Bayes method for ADE estimation and inference. Please note that the dose here not refer 
to the traditional drug dose. Instead, the dose refers to the number of different drugs co-
administrated by the patients. 
Myopathy, a muscle pathology that can progress to rhabdomyolysis (i.e., a rapid 
destruction of skeleton muscle), is an appropriate example to demonstrate the application 
of a high-dimensional drug interaction model (Chatzizisis et al., 2010). Among 7 million 
FDA spontaneous ADE case reports from 2001-2010, around 100,000 of these concerned 
myopathy. Among 1634 FDA-approved drugs, 75 drug labels now list myopathy as a 
potential side effect, including the important drug class of statins (lipid-lowering 
medications), which have a reported myopathy frequency of 5% (Graham et al., 2004). 
Considering that more than 18% of Americans over the age of 45 (i.e., 127 million) took 
statins in 2012, the potential annual number of U.S. myopathy cases could reach 1.15 
million. To further investigate this statin-myopathy association, we recently identified six 
novel drug interaction pairs that significantly increased myopathy risk above a mere 
additive risk from two single drugs taken separately, using a local medical records database 
at Indiana University (Duke et al. 2012). 
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3.2.   Data description and preprocessing 
3.2.1.   Indiana Patient Care Data (INPC) 
The Indiana Network for Patient Care (INPC) is a heath information exchange data 
repository containing medical records for over 15 million patients throughout the state of 
Indiana.  The Common Data Model (CDM) is a derivation of the INPC containing coded 
prescription medications, diagnoses, and observational data for 2.2 million patients 
between 2004 and 2009.  The CDM contains over 60 million drug dispensing events, 140 
million patient diagnoses, and 360 million clinical observations (e.g., laboratory results, 
diagnose codes, medications).  These data were anonymized and architected specifically 
for research on adverse drug reactions through collaboration with the Observational 
Medical Outcomes Partnership project (OMOP). 
3.2.2.   Myopathy definition 
Myopathy has a number of potential clinical manifestations. This phenotype is 
mapped to the INPC CDM condition concept IDs (Table 3.1). The same myopathy terms 
are also used in the FDA Adverse Event Reporting System (FAERS) to define the cases. 
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Table 3.1 Myopathy frequency in the INPC-CDM data set 
Myopathy 
Category 
Myopathy Concept ID Frequency 
446370 
Antilipemic and antiarteriosclerotic drugs 
causing adverse effects in therapeutic use 
206 (0.025%) 
4262118 Other myopathies 7 (0.00084%) 
80800 polymyositis 372 (0.045%) 
73001 Myositis 53 (0.0064%) 
84675 Myalgia and myositis 48877 (5.9%) 
4217978 Myalgia and myositis, unspecified 185 (0.022%) 
439142 Myoglobinuria 52 (0.0063%) 
4147768 Myopathy, unspecified 1 (0.00012%) 
4345578 Rhabdomyolysis 52 (0.0063%) 
4248141 Rhabdomyolysis 1 (0.00012%) 
79908 Muscle weakness 12720 (1.5%) 
4218609 Muscle weakness (generalized) 22 (0.0027%) 
Yes Any myopathy categories 59,572 (7.2%) 
No  769,333 (92.8%) 
 
3.2.3.   Data preprocessing  
Myopathy events and drug exposures among patients having a myopathy event, the 
drug-condition relationship is anchored by its date in the database.  For our analysis, any 
drug exposure occurring within a one-month window before the diagnosis of myopathy 
was considered a positive exposure. For a hypothesized drug pair (drug1, drug2), if only 
one drug was administrated in the drug exposure window, it was defined as a single drug 
exposure; if both drugs were administrated within a specific window, it was defined as a 
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two-drug exposure; if neither drug was administered within the one-month window, it was 
defined as non-exposure.  
Two types of new events were defined. The first type was the first event. However, 
patients whose first myopathy event was within the first six months of the database were 
excluded, we could not rule out additional myopathy events prior to the starting date of the 
database (01/01/2004). The second event type included any follow-up myopathy event 
whose corresponding drug exposure was more than 6 months after the previous myopathy 
event. In other words, the second type of new myopathy event required a “washout” period 
(i.e., no drug exposure) of more than 6 months. 
All patients who experienced new myopathy events were selected as cases. Patients 
who did not experience myopathy served as negative controls. For a control patient, an 
index time was randomly selected from the new myopathy event times from the cases. 
Anchored by this index time, a one-month drug exposure window was defined. Then, 
exposure to a single test drug, two drugs, or neither drug was defined in the same manner 
as for the cases. 
3.3.   Method 
3.3.1.   A mixture dose response model 
For each drug combination, the frequencies that particular combination appeared in 
case and control populations were considered outcomes, for subsequent analysis. Let 𝑦𝑖𝑗 
and 𝑛𝑖𝑗 − 𝑦𝑖𝑗  be the outcomes, correspond to case and control populations, for 𝑗 th 
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component [𝑗 = 1,2, …  (
20
𝑖
)]  in 𝑖 -way drug combination. Since the outcome clearly 
follows a binomial distribution, a generalized linear model approach was needed. In fact, 
we used a two-component mixture of logistic regression. Each outcome could be attributed 
to either of two groups: fixed curve or dose response curve. Then the probability 
distribution function of 𝑦𝑖𝑗 can be expressed in equation (3.1). 
 
𝑃(𝑦𝑖𝑗) = 𝑃 × [(
𝑛𝑖𝑗
𝑦𝑖𝑗
) 𝜋𝑑𝑜𝑠𝑒
𝑦𝑖𝑗 (1 − 𝜋𝑑𝑜𝑠𝑒)
(𝑛𝑖𝑗−𝑦𝑖𝑗)] + (1 − 𝑃)
× [(
𝑛𝑖𝑗
𝑦𝑖𝑗
) 𝜋𝑓𝑖𝑥𝑒𝑑
𝑦𝑖𝑗 (1 − 𝜋𝑓𝑖𝑥𝑒𝑑)
(𝑛𝑖𝑗−𝑦𝑖𝑗)]. 
(3.1) 
Let covariate 𝑥 = 𝑖 be the number of co-medications, the probability under fixed curve 
model is constant as number of co-medication increased: 
 𝜋𝑓𝑖𝑥𝑒𝑑 =
exp(𝛽0)
1 + exp(𝛽0)
, (3.2) 
and the probability under dose-response curve model will be increased as number of co-
medication increased: 
 𝜋𝑑𝑜𝑠𝑒 =
exp(𝛽1 + 𝛽2𝑥)
1 + exp(𝛽1 + 𝛽2𝑥)
. (3.3) 
Thus the probability distribution function of 𝑦𝑖𝑗 given 𝜽 = (𝜋, 𝛽0, 𝛽1, 𝛽2) can be 
expressed as: 
 𝑃(𝑦𝑖𝑗|𝑥, 𝜽) = 𝑃 × 𝐴𝑖𝑗 + (1 − 𝑃) × 𝐵𝑖𝑗. (3.4) 
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Where in (3.4), 𝐴𝑖𝑗 = [(
𝑛𝑖𝑗
𝑦𝑖𝑗
) (
exp(𝛽1+𝛽2𝑥)
1+exp(𝛽1+𝛽2𝑥)
)
𝑦𝑖𝑗
(
1
1+exp(𝛽1+𝛽2𝑥)
)
(𝑛𝑖𝑗−𝑦𝑖𝑗)
] and 𝐵𝑖𝑗 =
[(
𝑛𝑖𝑗
𝑦𝑖𝑗
) (
exp(𝛽0)
1+exp(𝛽0)
)
𝑦𝑖𝑗
(
1
1+exp(𝛽0)
)
(𝑛𝑖𝑗−𝑦𝑖𝑗)
]. And the log-likelihood function is given by:  
 
𝑙(𝜽) = ∑ ∑ 𝑃(𝑦𝑖𝑗|𝑥, 𝜽)
(
20
𝑖
)
𝑗=1
6
𝑖=1
. (3.5) 
3.3.2.   EM-algorithm 
To find the maximum-likelihood estimates, we used an Expectation-
Maximization (EM) algorithm by defining 
𝑢𝑖𝑗 = {
1, if the combination follows a dose − response risk;
0, if the combination follows a fixed risk.                      
 
Since 𝑢𝑖𝑗 is unobservable, it is treated as a missing value, and the complete data is 
defined as 𝐷𝑐 = {𝒚, 𝒙, 𝒖}. Then the complete data log-likelihood is 
 
𝑙𝐶(𝜽) = ∑ ∑ {𝑢𝑖𝑗 log [(
exp(𝛽1+𝛽2 𝑥)
1+exp(𝛽1+𝛽2𝑥)
)
𝑦𝑖𝑗
(
1
1+exp(𝛽1+𝛽2𝑥)
)
𝑛𝑖𝑗−𝑦𝑖𝑗
𝑃] +
(
20
𝑖
)
𝑗=1
6
𝑖=1
(1 − 𝑢𝑖) log [(
exp(𝛽0)
1+exp(𝛽0)
 )
𝑦𝑖𝑗
(
1
1+exp(𝛽0)
)
𝑛𝑖𝑗−𝑦𝑖𝑗
(1 − 𝑃)]} + 𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑡𝑒𝑟𝑚. 
(3.6) 
E-Step: At the (𝑡 + 1)th iteration, we need to calculate 
 
𝑤𝑖𝑗
(𝑡) = 𝐸[𝑢𝑖𝑗|𝐷𝑐, ?̂?
(𝑡)] =
?̂?(𝑡)𝑓 (𝑦𝑖𝑗|𝑥𝑖, ?̂?1
(𝑡), ?̂?2
(𝑡))
?̂?(𝑡)𝑓 (𝑦𝑖𝑗|𝑥, ?̂?1
(𝑡), ?̂?2
(𝑡)) + (1 − ?̂?(𝑡))𝑓 (𝑦𝑖𝑗|𝑥𝑖, ?̂?0
(𝑡))
. (3.7) 
Where in (3.7), ?̂?(𝑡) is the maximum likelihood estimator obtained in iteration 𝑡.  
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M-Step: We replace the missing value 𝑢𝑖𝑗 by 𝑤𝑖𝑗
(𝑡)
 in the complete log-likelihood function 
(3.6). Then we maximize the function: 
 
𝑄(𝑡) = ∑ ∑ {𝑤𝑖𝑗
(𝑡)
log [(
exp(𝛽1 + 𝛽2 𝑥)
1 + exp(𝛽1 + 𝛽2𝑥)
)
𝑦𝑖𝑗
(
1
1 + exp(𝛽1 + 𝛽2𝑥)
)
𝑛𝑖𝑗−𝑦𝑖𝑗
𝑃]
(20
𝑖
)
𝑗=1
6
𝑖=1
+ (1 − 𝑤𝑖𝑗
(𝑡)) log [(
exp(𝛽0)
1 + exp(𝛽0)
 )
𝑦𝑖𝑗
(
1
1 + exp(𝛽0)
)
𝑛𝑖𝑗−𝑦𝑖𝑗
(1 − 𝑃)]} . 
(3.8) 
Regular approaches can be used to obtain the maximum likelihood estimator of parameters 
in (3.8). Starting with proper initial estimates of the parameters, we iterate between E-step 
and M-step until convergence is achieved.  
3.3.3.    lFDR computation 
False discovery rate (FDR) can be considered as a by-product of the proposed 
mixture model. For the two-group model, we defined the “Bayesian FDR” for (𝒀 ≤ 𝒚) 
as: 
 
𝐹𝐷𝑅(𝑦) ≡
(1 − 𝜋)𝐹0(𝑦)
𝐹(𝑦)
= 𝑃{𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑙𝑙𝑜𝑤𝑠 𝑓𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑣𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛𝑠ℎ𝑖𝑝|𝑌 ≤ 𝑦}. 
(3.9) 
However, these tail areas are not very natural for Bayesian FDR estimation. Equation 
(3.9) can be defined as a general rejection region, consisting of infinitesimally “local” 
regions. Efron et al. (2001) defined the local false discovery rate (lFDR) as: 
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𝑙𝐹𝐷𝑅(𝑌) =
(1 − 𝜋)𝑓0(𝑌)
𝑓(𝑌)
. (3.10) 
And in our analysis, (3.10) can be written as:  
 
𝑙𝐹𝐷𝑅(𝑦𝑖𝑗) =
(1 − 𝑃) × 𝐴𝑖𝑗
𝑃 × 𝐵𝑖𝑗 + (1 − 𝑃) × 𝐴𝑖𝑗
. (3.11) 
Where in (3.11), 𝐴𝑖𝑗 = [(
𝑛𝑖𝑗
𝑦𝑖𝑗
) (
exp(𝛽1+𝛽2𝑥)
1+exp(𝛽1+𝛽2𝑥)
)
𝑦𝑖𝑗
(
1
1+exp(𝛽1+𝛽2𝑥)
)
(𝑛𝑖𝑗−𝑦𝑖𝑗)
]  and 𝐵𝑖𝑗 =
[(
𝑛𝑖𝑗
𝑦𝑖𝑗
) (
exp(𝛽0)
1+exp(𝛽0)
)
𝑦𝑖𝑗
(
1
1+exp(𝛽0)
)
(𝑛𝑖𝑗−𝑦𝑖𝑗)
]. 
3.4.   Results 
It is computationally challenging to investigate the effect of all possible 
combinations of drugs in the database. Consequently, in this paper, we limited our focus 
on a finite number of drugs and their high dimensional drug interactions. In particular, we 
emphasize the statistical aspects of high-dimensional drug interaction evidence, not the 
computational challenge. The subsequent paper in this journal will address the 
computational challenges (Du et al., 2015). To that end, the top 20 most frequently 
distributed drugs (Table 3.2) were selected and all possible two, three, four, five, and six 
drug combinations were considered and their frequencies determined in case control 
populations. For each drug combination, myopathy frequencies were computed. Figure 3.1 
illustrates the distribution of these proportions, showing that some drug combinations 
elevated myopathy risk upon increased co-administration of other drugs, while myopathy 
risk stayed constant for many other drug combinations, even with increased numbers of 
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co-committed drugs. This observation strongly motivated us to model myopathy risk using 
a mixture of two dose-response models. The dose means the number of co-committed drugs. 
One model followed a classical dose response curve, while the other model was constant 
(see Methods section for model specification). 
To estimate regression parameters (Table 3.3), we used the EM algorithm described 
in the Methods section. Specifically, we found that the mixing proportion π, the proportion 
of high dimensional drug interactions associated with a constant myopathy risk, was 0.093. 
The mixture logistic model suggested that some drug interactions follow a dose response 
curve. The mixture model was plotted in figure 3.1. 
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Table 3.2. Drug frequencies 
Drug name Frequency for 
case population 
Frequency for 
control population 
Acetaminophen 5570 35359 
Hydrocodone 4566 32079 
Simvastatin 4026 59346 
Alprazolam 3474 22964 
Tramadol 3410 16278 
Duloxetine 3322 13026 
Oxycodone 3299 16531 
Fluoxetine 2618 28871 
Zolpidem 2424 17580 
Ethinyl Estradiol 2419 65079 
Omeprazole 2389 20657 
Escitalopram 2322 26245 
Esomeprazole 2102 19803 
Promethazine 1849 16787 
Venlafaxine 1826 12570 
Amitriptyline 1774 8476 
Lansoprazole 1693 18322 
Tizanidine 1673 3336 
Ondansetron 1640 13425 
Atorvastatin 1599 21172 
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Table 3.3. Regression parameter estimates for the two mixture model 
types 
 
Parameter 
Logistic mixture 
Estimate Standard error P-value 
exp (𝛽0) 0.082 0.009 <<0.001 
exp (𝛽1) 0.139 0.009 <<0.001 
exp (𝛽2) 1.297 0.004 <<0.001 
 
 
Figure 3.1. Distribution of the proportion of affected individuals over different drug 
combinations. Fitted regressions for two groups are fitted on these boxplots. 
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Another important observation of the high-dimensional drug interaction dose response 
mixture logistic model was that myopathy risk increases as the dimension of drug 
interaction increases. The estimated maximum myopathy risk, around 40% for high 
dimensional drug interactions in our dose range, is a novel observation. 
The best feature of our proposed mixture model scheme was its estimation of the 
local false discovery rates (lFDRs) for all drug combinations, regardless of their 
dimensionality. Tables 3.4 to 3.8 show the minus log_10 transferred lFDRs for the top ten 
drug combinations. It is clear that our model can provide accurate lFDR estimates across 
various dimensional DDIs. In fact, all the reported top 10 drug interactions from 2-way to 
6-way drug interactions all had lFDRs of less than 5%. We further evaluated the top ranked 
drug interaction signals using the Side Effect Resource (SIDER) database 
(sideeffects.embl.de), finding that all the top 10 drug interactions, from 2-way to 6-way, 
contained drugs with myopathy risks previously reported in the SIDER database. These 
findings strongly confirmed that our high dimensional drug interactions present true 
myopathy risks previously associated with single drugs. 
Many instances were found that the increased number of co-committed drugs led 
to increased myopathy risk. For example, the myopathy risk is 0.20 for duloxetine, 0.12 
for hydrocodone, and 0.16 for oxycodone. Then, the myopathy risk for taking duloxetine 
and hydrocodone together is 0.30, duloxetine and oxycodone together is 0.34, hydrocodone 
and oxycodone together is 0.21. If all three drugs are taken together, their myopathy risk 
becomes 0.35. Thus, their myopathy risk increases as the number of drug combination 
increasing (Figure 3.2). 
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Table 3.4. Top 2-drug combinations showing increased risk, based on lFDR 
values. Bold represents drug combinations reported for myopathy in SIDER 2. 
 
Drug_1 Drug_2 Sample Size − 𝐥𝐨𝐠𝟏𝟎 𝒍𝑭𝑫𝑹 Risk 
Oxycodone Acetaminophen 9384 260.824 0.186 
Alprazolam Acetaminophen 6092 207.978 0.200 
Hydrocodone Duloxetine 2582 203.956 0.298 
Oxycodone Duloxetine 1958 190.879 0.339 
Tramadol Duloxetine 1812 190.109 0.355 
Hydrocodone Oxycodone 4726 171.270 0.205 
Hydrocodone Alprazolam 5296 167.413 0.194 
Oxycodone Alprazolam 2949 166.647 0.249 
Tramadol Acetaminophen 5981 147.900 0.179 
Zolpidem Acetaminophen 3695 142.290 0.209 
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Figure 3.2. The risks of a single drugs, 2-drug combinations, and 3-drug combination 
of duloxetine, hydrocodone, and oxycodone. 
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3.5.   Conclusion and discussion 
In this study, a mixture dose response model was developed to model high-
dimensional drug interactions. We used myopathy as the ADE to exemplify a common 
pathology found in electronic medical records databases. This mixture model framework 
could accurately estimate the false discovery rate of high dimensional drug interactions, 
significantly improving the utility of our mixture model. The dose response component of 
our mixture model suggested that the maximum myopathy risk was close to 40%. By using 
a complimentary algorithm for high dimensional drug interactions, we determined the 
effects of drug interactions on myopathy risk. 
One limitation of our current statistical model is that it can accommodate only a 
finite number of drugs and their higher order drug interactions. However, we were still able 
to analyze the top 20 drugs with the highest frequencies. In order to expand the analysis to 
all drugs, more sophisticated computational algorithms are needed. A second limitation is 
that the current model does not account for confounding variables. Like many other 
pharmacovigilance data analyses, our proposed associations between ADEs and high 
dimensional drug interactions need further molecular experimental validation, and using a 
more stringent pharmaco-epidemiological study design and alternative databases. Thirdly, 
the common data model derived database from Indiana Patient Care Data contains only the 
structured diagnosis and medications. We cannot go back, and verify the accuracy of 
myopathy definition. Hence, the potential misclassification of the ADE is another 
limitation. Finally, our model cannot provide a directionality of different drugs in a drug 
combination. This problem will be address in the subsequent paper in this journal. Despite, 
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these limitations, we believe our approach has high potential for determining adverse drug 
effects (not only myopathy) associated with the combination of a large number of drugs 
that might be co-prescribed for patients suffering from specific conditions (e.g., diabetes, 
hypertension, etc.). 
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Chapter 4. Cost-efficient Designs for Pharmacogenomics Studies 
Summary: Pharmacogenomics studies have successfully identified several genetic markers 
that associated with drug responses in the past decades. With more and more 
pharmacogenomics studies carried out, medical researchers are able to achieve maximized 
efficacy and minimized adverse drug reactions for each individual. Hence, the splendid 
future of personalized medicine is dawning. Currently, genotyping cost is still a major 
concern for large scale population based pharmacogenomics studies. In this research, we 
proposed a cost-efficient design for discover and testing genetic associations between 
single nucleotide polymorphism (SNP) markers and drug response. The proposed design 
is made up of a marker screening stage and marker validation stage. Pooled DNA 
sequencing will be used to screen markers with evidence of association in a portion of 
sample. For marker validation, selected markers will be genotyped via SNP array for all 
samples. Theoretical relation between the test statistics for the two stages were derived and 
these properties were examined in multiple simulation studies. Finally, optimal designs 
under different scenarios were given. 
4.1.  Introduction 
Current clinical practices faced significant challenges from individual variabilities 
in drug efficacy and drug safety (Ma and Lu, 2011). Valuable knowledges to explain such 
heterogeneities have been gathered during the past years via pharmacogenomics studies, 
in which the role of genetics in drug response had been investigated (Ritchie, 2012). In 
Population-based pharmacogenomics studies, suspicious genomic regions will be 
identified through testing for correlations between phenotypes and genetic markers. Such 
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genetic markers are usually single nucleotide polymorphisms (SNPs), as their biological 
importance had been well recognized (Hirschhorn et al., 2002). In 2005, a first genome 
wide association (GWA) study had been conducted (Haines et al., 2005) and it was 
considered as a revolution on genetic association study. In a few years, the implementation 
of GWA studies on pharmacogenomics had successfully identified several novel 
associations between drug responses or reactions and clinically relevant genetic loci (Daly, 
2010). Meanwhile, over 1,200 other GWA studies have been performed and 4,000 SNP 
associations have been identified within a few years (Johnson and O'Donnell, 2009). 
Besides these contributions, scientists realized that SNP associations explained only a 
modest fraction of heritable variation in phenotype (McCarroll, 2008). Instead of using 
SNPs as markers, pharmacogenomics studies based next generation sequencing (NGS) 
technologies enabled catching rare functional variants to have relatively large effects 
(Cirulli and Goldstein, 2010). With these rapidly developing technologies, 
pharmacogenomics studies now offer significant potential for subsequent clinical 
applications and hence play an importance role on the implementation of personalized 
medicine (Wei, 2012 and Crews et al., 2012).  
During the past few years, costs of genotyping are sharply decreased. However, 
many other factors still keep the cost as a major concern for population based 
pharmacogenomics study, as well as other kinds of genetic association studies. For instance, 
sophisticated molecular and cellular biology experiments, such as chromosome sorting, to 
prepare the library for sequencing, thus adding considerably to the overall experimental 
costs (Sboner et al., 2011). DNA pooling and two-stage design have been demonstrated as 
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two practical cost-efficient approaches for large scale genetic association studies, as they 
could maintain decent statistical powers to detect biological meaningful markers.  
One of the most commonly applied approach in genetic association studies is to 
compare the minor allele frequencies (MAFs) of SNPs between affected cases and 
unaffected controls. In such case-control studies, the key parameters, MAFs, can be 
obtained through genotyping either individual DNAs or DNA pools. Compared with 
individual genotyping, unequal individual DNA contributions in a DNA pool may cause 
the estimated MAFs to have increased variances. However, such drawback can be 
minimized in well-designed large scale high throughput association studies (Norton et al., 
2004). Moreover, evidence shown that the variations introduced by unequal individual 
DNA contributions is not a significant problem for carefully constructed DNA pools 
(Macgregor, 2007). For SNP array based association study, a comprehensive review of 
methods to analyze outcomes from pooled DNA samples can be find in Sham et al. (2002). 
For NGS technology, pooled DNA sequencing (pooled-seq) is also effective both for the 
discovery of rare alleles and the estimation of MAFs (Futschik and Schlötterer, 2010). 
MAF estimations based on sequencing of DNA pools (pooled-seq) are influenced by even 
more factors, such as sequencing depth and sequencing error rate etc. Gautier et al. (2013) 
initially provided detailed statistical properties for the MAFs that estimated from pooled-
seq, in which the ratio of observed count of reads supporting the minor allele to the 
observed count of all reads at a base pair was demonstrated to be unbiased estimator for 
the MAF of that allele. Based on parametric assumptions, observed likelihoods (obtained 
by integrating out the latent individual contributions in DNA pools) for sequencing reads 
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from pooled-seq under the null and alternative hypothesis can be used to test for 
associations (Kim et al., 2012). 
On one hand, DNA pooling reduces the cost of a genetic association study by 
decreasing the number of samples to be genotyped or the number of libraries to be prepared. 
On the other hand, two-stage design cut down the number of markers to be evaluated. As 
its name, a two-stage design for genetic association study is composed by a stage for marker 
screening (stage one) and a stage or marker validation (stage two). Sogapanta et al. (2002) 
initially proposed a two-stage design for genetic association study. Under this approach, 
all markers will be screened among a portion of available samples in the first stage. In the 
second stage, the most significant M markers from stage one will be further validated 
among the remaining samples. The sample size and power calculation can be achieved by 
assuming either independency or a compound symmetric correlation structure between 
markers. Later, Sogapanta et al. (2003) extended her work with sample size constraints. At 
the same time, another pseudo likelihood based two-stage design for genetic association 
study was given by Thomas et al. (2004). Two years later, Skol et al. (2006) proposed a 
joint analysis approach. In the second stage, joint analysis tests the association by using a 
linear combination of the test statistics form both stages. With a significant reduction of 
the portion of markers evaluated, the statistical power for a two-stage design were shown 
to be even comparable to single stage design. Instead of selecting the top markers in stage 
one by order statistics, Skol et al. (2006) used a fixed threshold for P-values to screen 
markers. The advantage for this approach is that sample size and power can be directly 
calculated without any assumptions on the correlation structures between markers. The 
implementation of two-stage design and DNA pooling can be combined together to further 
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peruse cost efficiency. For SNP based association study, an example of such a study design 
with its statistical properties can be find in Zuo et al. (2006).  
Current researches on cost-efficient design heavily focused on the case-control 
based genetic association studies. Optimal case-control study designs under different 
conditions were developed (i.e. Skol et al., 2007; Zuo et al., 2008 and Wang et al., 2009). 
For pharmacogenomics studies, randomized clinical trials (RCTs) are considered as the 
gold standard of study designs among different epidemiology designs (Stolberg et al. 2004). 
RCTs are perspective cohort studies. With individual genotyping, recent studies examined 
the SNP drug adverse reaction associations within the active treatment arm of a RCT via 
regression models (i.e. Schneider et al., 2014). Conversely, pharmacogenomics researchers 
can divide subjects in the treatment arm into two groups by their responses to the drug 
(Weiss et al., 2001). DNA pooling can then by applied and the genetic association can be 
tested by comparing MAFs between cases and controls. One limit for this design is that the 
effect of different genetic models (dominant, recessive and gene dose) on clinical outcomes 
are not directly tested. In returns, the statistical powers to detect genetic associations will 
be compromised. Moreover, the statistical properties of a two-stage design involving 
pooled DNA sequencing are still under developing.  
In this article, we propose a two-stage genetic association study design for 
perspective cohort studies. In the first stage, markers will be screened by comparing the 
MAFs estimated from pooled-seq under a case-control design. In the second stage, 
promising markers will be individually genotyped. Regression models under different 
genetic models will be used to confirm associations.  
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4.2.  Method 
4.2.1.  Notations, definitions and assumptions 
In this article, we consider binary outcome and markers with two alleles. The 
following notations will be used. 𝑌 (phenotype) denotes the binary outcome. Subjects can 
be classified into either cases or controls by 𝑌 = 1  or 0 . 𝜋𝐷 = 𝑃(𝑌 = 1)  denotes the 
prevalence. 𝑁 denotes the sample size. 𝑆𝑃 denotes the pool size in pooled DNA sequencing 
(pooled-seq) and 𝑁𝑃 denotes the count of pools. 
We assume the candidate markers are at Hardy-Weinberg Equilibrium. For a 
marker, the major allele is denoted by 𝐴 with frequency 𝑝 and the minor allele is denoted 
by 𝑎 with frequency 𝑞 = 1 − 𝑝. 𝐺 (genotype) is the count of minor alleles carried by a 
subject (𝐺 = 0,1 or 2). 𝑍 is the covariate based on different genetic models (dominant, 
recessive or gene dose). Relation between 𝐺  and 𝑍 with their expected frequencies are 
showing in table 4.1. 
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Table 4.1. Relation between genotype and covariate under different genetic 
model with expected frequencies 
Genotype 𝐺 
Covariate 𝑍 
Frequency 
Dominant Recessive Dose 
AA 0 0 0 0 𝑝2 
Aa 1 1 0 1 2𝑝𝑞 
aa 2 1 1 2 𝑞2 
 
𝜋1 = 𝑃[𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎|𝑌 = 1]  and 𝜋0 = 𝑃[𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎|𝑌 = 0]  are the minor allele 
frequencies (MAFs) among cases and controls. 𝜋𝛿 = 𝜋1 − 𝜋0  denotes the difference 
between MAFs in case and control. For a particular genetic model, penetrance for the 𝑖th 
(denoted in subscript) subject given his covariate 𝑍𝑖 is assumed to follow the logistic model 
(4.1).  
 log (
𝜋𝐷,𝑖
1−𝜋𝐷,𝑖
) = 𝛽0 + 𝛽1𝑧𝑖, 𝜋𝐷,𝑖 = 𝑃(𝑌𝑖 = 1|𝑍𝑖). (4.1) 
Let 𝑅 be the observed count of reads at a locus from pooled-seq. While, let 𝐶 be 
the count of reads supporting minor allele 𝑎. The following assumptions for the sequencing 
reads from pooled-seq are made.   
a) Individual contributions in a DNA pool are assumed to follow a Dirichlet distribution 
such that 𝑫~𝐷𝑖𝑟(𝑆𝑃, 𝜅). The MAF within a DNA pool is 𝑣 = ∑
𝑔𝑖𝑑𝑖
2
 𝑆𝑃𝑖  (∑ 𝑑𝑖
𝑆𝑃
𝑖=1 = 1). 
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The variation of 𝑣 can be decomposed to sampling variation and pooling variation. The 
ratio of pooling variation to sampling variation is 
𝑆𝑃−1
𝜅𝑆𝑃+1
. 
b) 𝑅 follows Poisson distribution with mean 𝜆. The expected sequencing depth 𝜆 follows 
gamma distribution such that 𝑓(𝜆) =
𝛽𝛼
Γ(𝛼)
𝜆𝛼−1𝑒−𝛽𝜆, 𝜆 > 0. The ratio of 𝑉𝐴𝑅(𝑅) to 
𝐸(𝑅) is 
1+𝛽
𝛽
. 
c) Sequencing error rates are 𝜔𝐴 = 𝑃(𝑟𝑒𝑎𝑑 = 𝑎|𝑎𝑙𝑙𝑒𝑙𝑒 = 𝐴)  and 𝜔𝑎 = 𝑃(𝑟𝑒𝑎𝑑 =
𝐴|𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎). Given the sequencing error rates, 𝐶 follows binomial distribution such 
that 𝐶~Bin[𝑅, 𝑣(1 − 𝜔𝑎) + (1 − 𝑣)𝜔𝐴]. 
Detailed derivations for the properties in this section and the following sections can be find 
in Appendix B. We further assume the variations introduced by (a), (b) and (c) are 
independent with each other.  
Even though the cost of NGS can be measured by per genome, such a cost can be 
further decomposed into cost of library preparation and cost of sequencing. Additionally, 
the cost of sequencing is detrained by the cost of a machine run for a sequencing platform. 
The proposed design involved both pooled-seq and SNP array based genotyping. For 
pooled-seq, let 𝜃1 be the cost of library preparation for a DNA pool and 𝜃2 be the cost of a 
machine run for a sequencing platform. Individual genotyping can be obtained by 
customized arrays. Its cost can be measured in dollars per mark. Genotyping more markers 
usually resulted in lesser per-marker cost. Let 𝜃3 to be the per-marker cost of SNP array 
based genotyping. Through this dissertation, all the costs are in US dollars. The genotyping 
costs for NGS technology and SNP array technology offered from different research 
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universities have been queried. For detailed information on genotyping cost, please visit 
Appendix C. 
4.2.2.  The proposed two-stage design 
In the following sections, we use a superscript ∗ to indicate statistics and random 
variables appeared in the first stage. Suppose DNAs are available from 𝑁 subjects and 𝑁∗ 
subjects will be involved in the first stage (𝑁∗ = 𝑁𝑟, 0 < 𝑟 ≤ 1). These 𝑁∗ subjects can 
be classified into 𝑁1
∗ = ∑𝑦𝑖
∗ cases and 𝑁0
∗ = 𝑁∗ − 𝑁1
∗ controls. Their DNAs are pooled 
into 𝑁𝑃1
∗  pools of cases and 𝑁𝑃0
∗  pools of controls. For the sake of simplicity, we assume 
that the pools have same size 𝑆𝑃 with 𝑁1
∗ = 𝑁𝑃1
∗ × 𝑆𝑃 and 𝑁0
∗ = 𝑁𝑃0
∗ × 𝑆𝑃. In stage one 
(marker screening), 𝑀 variants are going to be called from pooled-seq. Marker screening 
will be based on comparing the estimated MAFs between cases and controls. Candidate 
markers will be selected based on a prefixed threshold (i.e P-value<0.05). 
In the second stage (marker validation), the selected markers will be individually 
genotyped for all 𝑁 subjects. Under each genetic model, the genotypes 𝐺𝑖s for any all 
individuals will be transferred into the covariates 𝑍𝑖 s accord to table 4.1. Logistic 
regression will be used to conduct hypothesis testing and confirm associations between 
markers and phenotypes. Similarly, for the sake of simplicity, the demographic variables 
of the subjects will not be considered in the logistic model. Adjustment have to be made 
for testing 𝑀 genetic markers simultaneously. Here we adopt a Bonferroni correction to 
control the familial wise error rate. Finally, any marker with a P-value less than 𝛼 𝑀⁄  will 
be claimed to associated with the phenotype. 
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4.2.3.  Properties of the proposed design 
4.2.3.1.  Marker screening and validation 
By dividing the subjects into two groups, theoretical values of 𝜋1  and 𝜋0  for a 
marker are 
 
𝜋1 =
𝑃(𝑌=1|𝐺=2)𝑃(𝐺=2)+
1
2
𝑃(𝑌=1|𝐺=1)𝑃(𝐺=1)
∑ 𝑃(𝑌=1|𝐺=𝑖)𝑃(𝐺=𝑖)2𝑖=0
 and  
𝜋0 =
𝑃(𝑌=0|𝐺=2)𝑃(𝐺=2)+
1
2
𝑃(𝑌=0|𝐺=1)𝑃(𝐺=1)
1−∑ 𝑃(𝑌=1|𝐺=𝑖)𝑃(𝐺=𝑖)2𝑖=0
. 
(4.2) 
The estimators of 𝜋1 and 𝜋0 proposed by Gautier et al. (2013) are 
 ?̃?1
∗ =
∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
𝑁𝑃1
∗  and ?̃?0
∗ =
∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
𝑁𝑃0
∗ . 
(4.3) 
Thus, ?̃?1
∗ and ?̃?0
∗ are the average of estimated MAF from DNA pools of cases and 
controls. Following the assumptions in section 4.2.1, the expectation of ?̃?𝛿
∗ = ?̃?1
∗ − ?̃?0
∗ is 
 𝐸(?̃?𝛿
∗) = (𝜋1 − 𝜋0) × (1 − 𝜔𝐴 − 𝜔𝑎) (4.4) 
And the variance of ?̃?𝛿
∗  can be approximate by (for large 𝑁∗):  
𝑉𝐴𝑅(?̃?𝛿
∗) = [(1 − 𝜛) × (1 − 𝜔𝐴 − 𝜔𝑎)
2 × (1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
)] × [
𝜋1(1 − 𝜋1)
2𝑁∗ × 𝜋𝐷
+
𝜋0(1 − 𝜋0)
2𝑁∗ × (1 − 𝜋𝐷)
] 
 
+2𝑆𝑝𝑜𝑜𝑙 × 𝜛 × {
[𝜔𝐴 + 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)]
2𝑁∗ × 𝜋𝐷
+
[𝜔𝐴 + 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)]
2𝑁∗ × (1 − 𝜋𝐷)
} 
(4.5) 
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Where in (4.5), 𝜛 =
𝛼𝛽+𝛽2+1
𝛼2
. By using the sample variances 𝑉𝐴?̂?(?̃?1
∗) and 𝑉𝐴?̂?(?̃?0
∗), the 
following statistic, 𝛿𝐻1
∗ , can be used to screen markers. 
 
𝛿𝐻1
∗ =
?̃?1
∗ − ?̃?0
∗
√
𝑉𝐴?̂?(?̃?1
∗)
𝑁𝑃1
∗ +
𝑉𝐴?̂?(?̃?0
∗)
𝑁𝑃0
∗
,  
(4.6) 
Under a certain genetic model, the logistic regression model to validate the genetic 
associations is 
 log (
𝜋𝑖
1 − 𝜋𝑖
) = 𝛽0 + 𝛽1𝑧𝑖, 𝜋𝑖 = 𝐸(𝑌𝑖 = 1|𝐺𝑖). (4.7) 
The statistics to test the hypothesis of association is  
 
𝛿𝐻2 =
?̂?1
√𝑉𝐴?̂?(?̂?1)
. 
(4.8) 
4.2.3.2.  Joint distribution for 𝛿𝐻1
∗  and 𝛿𝐻2 
If individual genotypes are observed in stage one, maximum likelihood estimators 
(MLEs) of 𝜋1 and 𝜋0 are  
 ?̂?1
∗ =
∑ 𝑔1,𝑖
∗𝑁1
∗
𝑖=1
2𝑁1
∗  and ?̂?0
∗ =
∑ 𝑔0,𝑖
∗𝑁0
∗
𝑖=1
2𝑁0
∗ . (4.9) 
The expectation and variance of ?̂?𝛿
∗ = ?̂?1
∗ − ?̂?0
∗ are 
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 𝐸(?̂?𝛿
∗) = 𝜋1 − 𝜋0 and 𝑉𝐴𝑅(?̂?𝛿
∗) ≈
𝜋1(1−𝜋1)
2𝑁∗×𝜋𝐷
+
𝜋0(1−𝜋0)
2𝑁∗×(1−𝜋𝐷)
. (4.10) 
?̂?𝛿
∗  and  ?̂?1 have an asymptotic joint normal distribution as shown in (11): 
 [
𝑉𝐴𝑅[?̂?𝛿
∗] 0
0 𝑉𝐴𝑅(?̂?1)
]
−1/2
([
?̂?𝛿
∗
 ?̂?1
] − [
𝐸(?̂?𝛿
∗)
𝛽1
])~𝑁 ([
0
0
] , [
1 𝜌
𝜌 1
]). (4.11) 
In (4.11), 𝑉𝐴𝑅(?̂?1) =
1
𝑁
𝐸[𝑉𝐴𝑅(𝑌)]
𝐸[𝑉𝐴𝑅(𝑌)]𝐸[𝑍2×𝑉𝐴𝑅(𝑌)]−{𝐸[𝑍×𝑉𝐴𝑅(𝑌)]}2
. Under null hypothesis (no 
association), 𝜌 =
√𝑁∗
√𝑁
𝐶𝑂𝑅(𝐺, 𝑍). In order to find the asymptotic distribution of ?̃?𝛿
∗  and ?̂?1, 
we assume  ?̃?𝛿
∗ = ?̂?𝛿
∗ + 𝜖∗ and 𝜖∗~𝑁(?̃?∗, [?̃?∗]2). From this assumption, 𝛿𝐻1 and 𝛿𝐻2 have 
a asymptotic joint normal distribution with correlation 𝜚 = 𝜌√
𝑉𝐴𝑅(?̂?1−?̂?0)
𝑉𝐴𝑅(?̃?1−?̃?0)
.  
In study design, the parameters 𝜇∗ and ?̃?∗ can be determined by (4.4), (4.5) and 
(4.10) for sample size and power calculation. In analysis, ?̂? and 𝑉𝐴?̂?(?̂?1 − ?̂?0) can be 
calculated in the second stage, as the individual genotype are known in this stage. Then ?̂? 
can be used to determine the P-value.   
4.2.3.4.  Type-1 error rate and power  
Let 𝑐𝐻1 be the threshold in stage one and 𝑐𝐻2 in stage two. For a candidate marker, 
inference is based on 𝛿𝐻1
∗  and 𝛿𝐻2 × 𝐼(|𝛿𝐻1
∗ | > 𝑐𝐻1). The type-1 error rate can be written 
as 
 𝑃[(|𝛿𝐻1
∗ | > 𝑐𝐻1, |𝛿𝐻2| > 𝑐𝐻2, Sign(𝛿𝐻1
∗ ) = Sign(𝛿𝐻2))|No association]. (4.12) 
The power can be written as 
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 𝑃[(|𝛿𝐻1
∗ | > 𝑐𝐻1, |𝛿𝐻2| > 𝑐𝐻2, Sign(𝛿𝐻1
∗ ) = Sign(𝛿𝐻2))|Association]. (4.13) 
4.2.4.  Cost evaluation and optimization 
We assume only a small portion of markers will be validated in stage two. Thus, 
only 𝜃1 and 𝜃2 depends on the setup of the study. For sequencing platforms, usually total 
throughput is fixed. The production of number of samples (DNA pools) to be sequenced, 
expected sequencing depth and length of genome to be sequenced is expected equal to a 
whole number multiple of platform runs. On designing the study, the expected total cost 
for genotyping is 
 
Cost =
𝑁∗
𝑆𝑃
𝜃1 +
Depth ×
𝑁∗
𝑆𝑃
× Length
Throughput
𝜃2 + 𝑁 × 𝑀 × 𝑃(|𝛿𝐻1
∗ | > 𝑐𝐻1) × 𝜃3 
(4.14) 
In (4.14), 𝑀 is proportional to the genome length. The three terms in (4.14) respectively 
denote the cost for library preparation (stage one), DNA sequencing (stage one), 
genotyping by SNP array (stage two). With any given restrictions (sample size or cost), 
optimized designs can be found via grid searching.   
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4.3.  Simulation studies 
In this section, we conduct extensive simulation studies to evaluate different 
properties of the proposed design under a few reasonable scenarios. Since the proposed 
method doesn’t rely on any correlation structure between genetic markers, we use 
Bonferroni-adjusted threshold to evaluate the empirical type-one error rates and powers for 
a single marker. For the remaining sections, we define the penetrance for subjects with 𝑍 =
0  to be πD_null = 𝑃(𝑌 = 1|𝑍 = 0) =
𝑒𝛽0
1+𝑒𝛽0
. For the recessive model, the study of 
association for rare alleles (MAF ≤ 0.01) would need a considerable large sample size. 
From such a point, only dominant model and gene dose model will be examined in 
simulation studies. 
For the setup of simulations, we assume the genome to be investigated contain five 
genes (total length equals to 150,000 base pairs). Further, we select a reasonable scenario 
as the following: 
1. For the sample sizes and pool size, we assume 𝑁 = 2,000, 𝑁∗ = 1,500, 𝑆𝑃 = 5. Hence, 
the number of DNA pools is 𝑁𝑃
∗ = 300. 
2. For the genetic markers, we assume 𝑀 = 100 (1 mutation per 1,500 base pairs) and set 
the threshold for marker screening to be 𝑐𝐻1 = 0.675, [𝑃(|𝛿𝐻1
∗ | > 𝑐𝐻1) = 0.5].  
3. For pooled-seq, we set the expected sequencing depth to be E(𝑅) = 100  and the 
variation of sequencing depth is 𝑉𝐴𝑅(𝑅) = 1.2 × 𝐸(𝑅).  
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4. For conducting DNA pools, we set 
𝑆𝑃−1
𝜅𝑆𝑃+1
= 0.2. Thus, the pooling variation is 20% of 
the sampling variation. In reality, pooling variation can be minimized for carefully 
conducted DNA pools (Macgregor, 2007). 
For the genotyping costs, we further assume that 𝜃1 = $300, 𝜃2 = $2,400 and 
𝜃3 = $0.5. The throughput of the sequencing platform is assumed to be 2,000,000×PE125 
reads per machine run. Here, PE refers to pair end sequencing. It is a standard sequencing 
procedure to help bioinformaticians on data processing. Under such assumptions, the 
genotyping cost for the proposed design is approximately $261,600. While, the genotyping 
cost for a conventional single-stage design (each individual DNA sample will be sequenced 
with a same expected sequencing depth) is $675,600.  
Since SNP array is a highly accurate genotyping technology, we assume there will 
be no genotyping errors in the second stage. Thus, we generate the data by the following 
order:  
1. For any individual, generating his/her genotype 𝐺𝑖 by a multinomial distribution with 
probability 𝑝2, 2𝑝𝑞 and 𝑞2. Selecting genetic model and use table 4.1 to determine the 
associated covariate 𝑍𝑖. 
2. For different values of 𝛽0 and 𝛽1, calculating the penetrance 𝜋𝐷,𝑖 = 𝑃(𝑌𝑖 = 1|𝑍𝑖) by 
model (4.1). Generating the binary outcome 𝑌  from a binary distribution with the 
probability of success equals to 𝜋𝐷,𝑖. 
3. Determine the subjects to be involved in stage one by sampling without replacement.  
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4. For the selected subjects involved in the first stage, form pools of cases and controls 
based on their status 𝑌∗s. Simulate individual contributions and calculate MAFs for 
each DNA pool according to the assumption (a) in section 4.2.1. 
5. Simulating observed reads 𝑅𝑖
∗𝑠 by Poisson gamma mixture according to the assumption 
(b) in section 4.2.1. Determine sequencing error rates, and generating 𝐶𝑖
∗𝑠 (the reads 
supporting minor allele) by the binomial distribution 𝐶~Bin[𝑅, 𝑣(1 − 𝜔𝑎) + (1 −
𝑣)𝜔𝐴] [assumption (d) in section 4.2.1].  
Based on the simulated data, we will examine the empirical type one error rate, empirical 
power and the properties for the proposed test statistics. 
4.3.1  Examine the empirical type-1 error rate under null 
Firstly, by Setting 𝛽1 = 0 on generating the phenotype, we compared the empirical 
type one error rates to the theoretical value 0.05 100⁄ = 0.0005. In each simulation, 𝛿𝐻1
∗  
and 𝛿𝐻2 × 𝐼(|𝛿𝐻1
∗ | > 𝑐𝐻1) will be calculated and used to test for association. The empirical 
type-1 error rate are computed as 
?̂? =
∑ 𝐼[𝛿𝐻2 × 𝐼(|𝛿𝐻1
∗ | > 𝑐𝐻1) > 𝑐𝐻2]
# 𝑜𝑓 𝑠𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑠
 
As the theoretical value is 0.0005, 100,000 simulations were conducted under different 
senarios. The empirical type-1 error rate with empirical 95% confidence intervals are 
shown in figure 4.1. In figure 4.1, three empirical estimates and empirical 95% confidence 
intervals are given under each scenario corresponding to different sequencing error rates 
(𝜔𝐴 = 𝜔𝑎 = 0; 𝜔𝐴 = 0.005 and 𝜔𝑎 = 0; and 𝜔𝐴 = 0 and 𝜔𝑎 = 0.005 respectively). For 
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common alleles (MAF>0.01), the confidence intervals for the empirical type one error rates 
are either covered or closed to the theoretical value. For rare alleles (MAF=0.01), the 
empirical type one error rates are shown to be conservative to the theoretical value. Such a 
phenomena are caused by sampling variations. For instance, alleles with very low MAF 
are more likely to be failed to catch for a limited sample size.  
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4.3.2  Examine the empirical power under different alternatives 
Secondly, we examine the empirical powers under different values of 𝛽1  for 
dominant and gene dose model. 5,000 simulations will be performed under each condition 
to get the empirical estimations of powers. The results are summarized in figure 4.2. The 
results shown that the proposed design has a comparable power to single stage design 
(under a same sequencing depth), while the cost for the proposed design is only 1/3 of the 
single stage design.  
Additionally, the impact on sequencing error rate on power have been examined. 
Sequencing error rates are determined by many factors. For illumine sequencing platforms, 
the standard per-base error rate are believed to be less the 1% (Wang et al., 2012).  We 
observed that technical errors are not going to undermine the power for both dominant and 
gene dose models. Such an observation coincide with equation (4.4), in which the bias are 
demonstrated to be comparatively small for lower sequencing error rate. 
For a reasonable penetrance rate (πDnull = 0.2 or 0.3), the empirical power to 
detect an association with OR=2 are always promised (even for rare alleles). However, the 
power to detect genetic associations under πDnull = 0.1 are poor. 
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4.3.3  Examine the empirical distribution of the test statistics 
Besides type one error rate and power, we also examined the empirical mean and 
standard deviation (SD) for the proposed statistics under a moderate minor allele frequency 
(MAF=0.05). We first compared the empirical estimations of the sample variance of ?̃?𝛿
∗  to 
its theoretical value in equation (4.5). Based on 5,000 simulations, the empirical standard 
deviations are shown to be consistent to the theoretical value (Table 4.2). Thus, marker 
screening based on the sample variances would not undermine the power calculated by (4.5) 
in the design stage.  
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Table 4.2. Simulated variances comparing to their theoretical values  
 
Dominant Model 
𝛽1 
sd(?̃?𝛿
∗) sd(?̂?𝛿
∗) 
Empirical (SD) Theoretical Empirical (SD) Theoretical 
0.50 0.0095  (0.00130) 0.0095 0.0084  (0.00072) 0.0084 
0.67 0.0103  (0.00127) 0.0102 0.0090  (0.00072) 0.0090 
0.80 0.0107  (0.00132) 0.0106 0.0094  (0.00071) 0.0094 
1.00 0.0113  (0.00134) 0.0112 0.0099  (0.00070) 0.0099 
1.25 0.0118  (0.00134) 0.0118 0.0105  (0.00070) 0.0104 
1.50 0.0122  (0.00138) 0.0122 0.0108  (0.00068) 0.0108 
2.00 0.0128  (0.00129) 0.0129 0.0114  (0.00066) 0.0114 
 
Gene Dose Model 
𝛽1 
sd(?̃?𝛿
∗) sd(?̂?𝛿
∗) 
Empirical (SD) Theoretical Empirical (SD) Theoretical 
0.50 0.0094  (0.00127) 0.0094 0.0083  (0.00071) 0.0083 
0.67 0.0102  (0.00130) 0.0101 0.0090  (0.00072) 0.0090 
0.80 0.0107  (0.00135) 0.0106 0.0094  (0.00073) 0.0094 
1.00 0.0113  (0.00134) 0.0112 0.0100  (0.00071) 0.0099 
1.25 0.0119  (0.00136) 0.0118 0.0105  (0.00069) 0.0105 
1.50 0.0123  (0.00137) 0.0123 0.0109  (0.00069) 0.0109 
2.00 0.0130  (0.00136) 0.0130 0.0115  (0.00068) 0.0115 
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For the correlation between 𝛿𝐻1
∗  and 𝛿𝐻2, the theoretical value under alternative is 
given in equation (B.22) (Appendix B). In the design stage, we suggested that the 
correlation under null can be used to compute powers for alternatives. The effect of such 
substitution were also examined in simulation studies. The empirical estimation of  
𝜚 and 𝜌 are closed to their theoretical values (Table 4.3). Thus, the correlation obtained by 
using 𝜌 =
√𝑁∗
√𝑁
𝐶𝑂𝑅(𝐺, 𝑍)  provide reasonable approximations for different alternatives. 
Hence, the sample size and power calculations will not be undermined. 
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Table 4.3. Simulated correlations comparing to their theoretical values 
 
Dominant Model 
𝛽1 
𝜚 𝜌 
Empirical (SD) Theoretical Empirical (SD) Theoretical 
0.50 0.7047  (0.018) 0.7581 0.8397  (0.007) 0.8549 
0.67 0.7314  (0.014) 0.7581 0.8502  (0.010) 0.8549 
0.80 0.7448  (0.014) 0.7581 0.8471  (0.009) 0.8549 
1.00 0.7456  (0.012) 0.7581 0.8480  (0.008) 0.8549 
1.25 0.7550  (0.011) 0.7581 0.8464  (0.006) 0.8549 
1.50 0.7609  (0.011) 0.7581 0.8538  (0.007) 0.8549 
2.00 0.7660  (0.011) 0.7581 0.8501  (0.007) 0.8549 
 
Gene Dose Model 
𝛽1 
𝜚 𝜌 
Empirical (SD) Theoretical Empirical (SD) Theoretical 
0.50 0.7228  (0.019) 0.7680 0.8479  (0.010) 0.8660 
0.67 0.7434  (0.011) 0.7680 0.8562  (0.006) 0.8660 
0.80 0.7556  (0.014) 0.7680 0.8597  (0.006) 0.8660 
1.00 0.7669  (0.017) 0.7680 0.8658  (0.007) 0.8660 
1.25 0.7576  (0.016) 0.7680 0.8575  (0.008) 0.8660 
1.50 0.7816  (0.015) 0.7680 0.8688  (0.009) 0.8660 
2.00 0.7607  (0.012) 0.7680 0.8633  (0.008) 0.8660 
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4.4.  Results 
In real clinical trials, the properties of a pharmacogenomics study (statistical power 
and genotyping cost) are affected by many factors. Many of this parameters are not 
controllable. For instance, biology parameters like the disease penetrance will not be 
determined by clinical investigators. The technical parameters (i.e. sequencing error rates) 
are determined by clinical investigators neither. Through simulation studies, the 
sequencing error rates are shown to have an ignorable effect on statistical power. In this 
section, the relations between the properties for different designs and controllable 
parameters will be investigated. These parameters involve the following: overall sample 
size (𝑁), sample size in stage one (𝑁∗), pool size (𝑆𝑃), threshold in stage one (𝑐𝐻1) and 
sequencing depth (𝛼 𝛽⁄ ). They usually can be determined independently by the clinical 
investigators. 
Here, we our efforts focuses on developing designs to detect functioning rare alleles. 
Only dominant and gene dose model will be explored, as recessive effect for rare alleles 
would need extreme large sample size to detect. Thus, through this section, we setup a 
reasonable scenario as the following: 
1. 𝜃1 = 300, 𝜃2 = 2400, 𝜃3 = 0.5. and the throughput are 2,000,000×PE125 reads.  
2. The genome to be sequenced containing 50 genes (length = 1,500,000 base pairs) and 
𝑀 = 3,000 (1 mutation per 500 base pairs). 
3. πDnull = 0.2,
𝑉𝐴𝑅(𝑅)
𝐸(𝑅)
= 1.2,
𝑆𝑃−1
𝜅𝑆𝑃+1
= 0.2 and 𝜔𝐴 = 𝜔𝑎 = 0. 
4. MAF for the mutation is 0.01. 
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4.4.1.  Example 1: relation between sample size and power 
In this example, we explore the relation between sample size and power for four 
different designs. They are: 
a) Conventional single stage design by using individual sequencing (40X coverage). The 
overall cost of this design is set to be 1. The cost of this design will be served as cost 
reference for the remaining three designs. 
b) Pooled single stage design by using pooled-seq ( 𝑆𝑃 = 8  and 100X coverage). 
Compared to (a), the cost of this design is approximately 0.22. 
c) The proposed design. In the first stage, pooled-seq will be used to screen markers. 
[𝑆𝑃 = 8, 100X coverage, 𝑁
∗ = 𝑁 and 𝑃(|𝛿𝐻1
∗ | > 𝑐𝐻1) = 0.05]. In the second stage, 
promising markers will be genotyped for all individuals by using SNP array. Compared 
to (a), the cost of this design is approximately 0.29. 
d) The proposed design. In the first stage, pooled-seq will be used to screen markers. 
[𝑆𝑃 = 8, 100X coverage, 𝑁
∗ = 0.75𝑁 and 𝑃(|𝛿𝐻1
∗ | > 𝑐𝐻1) = 0.1]. In the second stage, 
promising markers will be genotyped for all individuals by using SNP array. Compared 
to (a), the cost of this design is approximately 0.29.  
For design (a), testing of the genetic association will be based on the MLEs [equation (4.8)]. 
Equation (4.6) will be used to test the genetic association for design (b). The statistical 
inference for design (c) and (d) will be based on 𝛿𝐻1
∗  and 𝛿𝐻2. 
The relation between sample size and power to detect functioning rare allele 
(MAF=0.01) are illustrated in figure 4.3. In figure 4.3, we find that design (a), (c), (d) are 
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have almost same statistical powers, while the cost for the proposed design is only 29% 
compared to the conventional design. Though the cost of design (b) is closed to design (c) 
and (d), its statistical power is not comparable to the other designs. We also observed that 
an enlarged sample size is need for detecting rare allele in this scenario, even for 
conventional single stage designs. 
 
Figure 4.3. Relation of sample size and powers for design (a), (b), (c) and (d). The X-
axis is sample size and the Y-axis is the statistical power. The powers from cost 
efficient design are comparable to regular design. 
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4.4.2.  Example 2: relation between pool size and power/cost 
The parameters to determine statistical power and cost are overall sample size (𝑁), 
sample size in stage one (𝑁∗), pool size (𝑆𝑃), threshold in stage one (𝑐𝐻1) and sequencing 
depth (𝛼 𝛽⁄ ). In this example, we explore the relation between pool size and power/cost 
under the proposed design. We choose other parameters to be 𝑁∗ = 𝑁 = 5,000, 𝛼 𝛽⁄ =
50 and 𝑃(|𝛿𝐻1
∗ | > 𝑐𝐻1) = 0.1. By assuming the functioning rare allele (MAF=0.01) to hav 
a 2.5 odds ratio, the relation between pool size and power/cost illustrated in figure 4.4. As 
figure 4.4 shown, given a moderate coverage, the power will not significantly affected by 
pool size. However, by selecting an appropriate pool size, genotyping cost can be reduced 
by 10% to 40%. 
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Figure 4.4. Relation between pool size and power/cost 
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4.4.3.  Optimal designs under power constraint 
Given constraint on statistical power, we find optimal design with respect of cost 
on detecting a rare allele (MAF=0.01). Designs with optimized cost are obtained via grid 
searching. In this study, the space for different parameters are chosen as the following: 
sample size 𝑁 ∈ [1000, 8000], the portion of samples involved in the first stage (𝑁∗ 𝑁⁄ ) ∈
[0.3, 1] , pool size 𝑆𝑃 ∈ [2, 8] , threshold in stage one 𝑐𝐻1 ∈ [1.28, 1.96] , and the 
sequencing depth (𝛼 𝛽⁄ ) ∈ [50, 100]. The cost of all possible combinations of parameters 
within the parameter space will be computed and design with optimized cost will be 
reported.  
The optimal designs to have at least 70% statistical power on detecting a rare allele 
are given in table 4.4. We observed the optimal designs have 𝑆𝑃 = 8 and 𝑐𝐻1 = 1.96.  
Table 4.4. Designs with optimized cost to detect a functioning rare allele with OR=2.5 
Model 𝑁 𝑁∗ 𝑆𝑃 𝑐𝐻1 𝛼 𝛽⁄  Cost Power 
Dom 7,500 6,000 8 1.96 100 395K 0.703 
Dose 6,000 3,000 8 1.96 50 279K 0.70 
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4.4.4.  Optimal designs under genotyping cost constraint 
We further explored designs with optimal statistical power with different constrains on 
genotyping cost. Figure 4.5 demonstrates the relationship between cost and optimized 
statistical power to detect a rare allele with a 2.5 odds ratio. In figure 4.5, we observed that 
the power will be saturated as the genotyping cost increases. Further, table 4.5 presented 
the designs with optimized power for dominant and gene dose model respectively.  
 
Figure 4.5. Relation between cost and optimized statistical power to detect a rare allele 
with a 2.5 odds ratio 
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Table 4.5. Designs with optimized power to detect a functioning rare allele with 
OR=2.5 
Model 
Cost 
limit 
𝑁 𝑁∗ 𝑆𝑃 𝑐𝐻1 𝛼 𝛽⁄  Cost Power 
Dom 
500K 8,000 6,400 6 1.96 100 472K 0.79 
1M 8,000 6,400 4 1.96 100 793K 0.87 
Dose 
500K 8,000 6,400 6 1.96 80 495K 0.88 
1M 8,000 6,400 2 1.96 100 893K 0.89 
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4.5.  Conclusion 
In this study, we proposed a cost-efficient design for pharmacogenomics study or 
other genetic association studies. The proposed design involved both two-stage design 
approach and DNA pooling. In the first stage, pooled-seq will be used to detect variants 
and marker screening will be based on a two-sample 𝑧 test. In the second stage, promising 
markers will be genotyped by SNP array and logistic regression will be used to test genetic 
association. The asymptotic correlation between the test statistics in the first stage and 
second stage has been derived. The properties of the proposed design including type one 
error rate, statistical power and cost are given.  
In simulation studies, the empirical type one error rates are shown to be slightly 
conservative to the theoretical type one error. Thus, the proposed design controls type one 
error rates at the desired level. Further, the empirical powers form the proposed designs are 
shown to be comparable to conventional single stage designs, while the genotyping costs 
for the proposed design are reduced dramatically. Moreover, the empirical distributions for 
the test statistics in the first stage and second stage are investigated. Their empirical 
variances are shown to be consistent with theoretical value. A slight dispersion has been 
observed between the empirical correlations and theoretical correlations. It is caused by 
using the theoretical correlation under the null to approximate the theoretical correlation 
under alternatives. However, this approximation will not undermine the validity of the 
proposed design with respect to type one error rate and statistical power.  
The relation between sample size and power for detecting a functioning rare allele 
(MAF=0.01) has been shown in an example. The proposed design is shown to have almost 
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similar power compared to conventional design, while the cost for the proposed design is 
only 29% of the cost of conventional design. In this example, we also identify that an 
enlarged sample size are needed to detect a functioning rare allele for a phenotype with 
low penetrance. Additionally, the relations between pool size and power/cost are shown in 
other example. Finally, optimal designs under different scenarios have been obtained via 
grid searching. The cost to detect an association under gene dose model are slightly less 
than the cost to detect a dominant association. With a 1M cost constrain, we find that the 
statistical powers to detect functioning alleles are almost saturated at 90%. While, 
optimized power to detect functioning rare allele still need enlarged sample size. 
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4.6  Discussion 
In this research, we focusing on evaluate designs to detect rare alleles (MAF<1%). 
Under a dominant or gene dose model, a functioning allele with 1% MAF would cause 
approximately 2% of the population resulted in an alternative drug-response. With deeper 
understanding on pharmacogenomics, medications are moving towards the stage of 
personalized medicine (to maximize efficacy and minimize adverse drug reactions for) for 
each of us. The progressing of genotyping technologies makes the endeavor to personalized 
medicine even more promising. Studies have demonstrated more and more accurate 
relationship between pooled and individually determined allele frequencies (Schlotterer et 
al., 2014). However, the detection of functioning rare allele is still under varies challenges. 
Among those significant challenges, the most significant one is resource with respect to 
sample size and cost. Sample size and cost are correlated. For a fixed budget, reduced per-
individual cost can allow more samples to be enrolled for study. Meanwhile, rare alleles 
might be ignored as a consequence of stringent corrections for sequencing errors. Through 
this study, we observed that the cost to test genetic association studies can be optimized as 
a whole. Additionally, the test will not be undermined by technique biases for a large scale 
study.  
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Chapter 5.  Conclusion 
Tremendous efforts from medical researchers were offered to maximize drug 
efficacy and minimize adverse drug reaction for each individual (Mehta et al., 2011). A 
major obstacle towards such an aim is individual heterogeneities for drug responses. 
Moreover, the increasing trend of using polypharmacy makes the prediction of drug 
response even more complicated (Linjakumpu et al., 2002). Knowledges of drug responses 
can be gathered via both clinical trials and observational studies. Pharmacogenomics 
studies can be based on randomized clinical trials. On one hand, pharmacogenomics studies 
can serve as golden standard to establish causal relationships between a drug and an 
adverse drug adverse event (ADE). On the other hand, pharmacogenomics studies reveal 
the mechanism of the ADEs. Their findings can be used as feature guidelines for making 
prescriptions. Meanwhile, pharmacovigilance studies that based on SRS or other databases 
are typical observational studies. They are powerful tools for identifying post-marketing 
ADEs. SRS databases usually contain excessive amount of reports. Unlike clinical trials, 
such a feature enables uncommon or rare ADEs to be detected. Moreover, clinical trials to 
investigate drug adverse reaction and drug-drug interactions (DDIs) are limited by ethical 
and many other issues. Thus, population based pharmacovigilance studies play a crucial 
role on reducing unnecessary ADEs. 
In this research, we firstly proposed an empirical Bayesian mixture model (EBMM) 
for analyzing the FDA’s adverse event reporting (FAERS) system databases. FAERS 
reports contain on average four drugs and four ADEs. Such a feature makes the true drug-
ADE associations contaminated with noises introduced form co-medications. The 
proposed method classified drug-ADE pairs’ relative risks (RRs) into three groups 
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respectively as: a zero-risk group, a background noise group, and an increased risk group. 
The proposed method evaluates a drug-ADE pair’s association by its local false discovery 
rate (lFDR). The lFDR measures the posterior probability that the drug-ADE pair’s RR 
belongs to the background noise group. Thus, the proposed method is designed to 
distinguish significant drug-ADE associations from the background noises. Simulation 
studies demonstrated that the top-ranked drug-ADE associations from the proposed method 
had an outstanding portion of drug-ADE pairs’ RRs belonging to the increased risk group. 
While, another simulation study demonstrated that the empirical lFDRs are consistent with 
the model based lFDRs. Hence, the lFDR is a valid estimator of the posterior probability 
of a drug-ADE pair’s RR belonging to the noise group. Consequently, the proposed method 
were applied to the FAERS databases. Top-ranked drug-ADE associations for four general 
clusters of ADEs were validated by drug labels, in which a reasonable sensitivity had been 
observed. Both simulation and data analysis results demonstrated that the proposed method 
is more sensitive on selecting true drug-ADE signals. Additionally, ranking/generating 
signals by lFDR is more statistical interoperable and sound. 
Secondly, this research focused on the exploration of the functional relationship 
between increased dimensionality of drug interactions and ADE rates. A mixture dose-
response model was proposed by assuming the ADE risk is either escalates or remains 
constant as the dimensionality of DDIs increase.  Following the proposed model, the 
posterior probabilities of DDIs belonging to the constant risk group can be obtained. This 
quantity can be further used to detect DDIs to have an increased risk. The proposed method 
has been applied to a local electronical medical record (EMR) databases. By focusing on a 
common ADE myopathy, we observed that the expected myopathy risk increases as the 
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dimensionality of drug interaction (up to six drugs) increases. Such a relation has not been 
observed previously. Further, DDIs with increased myopathy risks were identified.  
Thirdly, a cost-efficient study design for pharmacogenomics studies has been 
proposed. The proposed design aimed towards a further cost-efficiency by combining two-
stage design approach and DNA pooling together. Two-stage design can reduce the cost 
for a pharmacogenomics studies by decreasing the number of markers to be genotyped. 
While, DNA pooling reduces the libraries to be prepared or DNA samples to be genotyped. 
The proposed design focuses on the detection of functioning rare alleles. Hence, the 
statistical properties of mutation detection and minor allele frequency (MAF) estimation 
by using pooled DNA sequencing were examined. Further, the relation between the test 
statistics to screen markers and the test statistics to confirm genetic association was 
established. The statistical properties for the proposed design including type one error rate, 
statistical power and cost are also given. Through simulation studies, the proposed design 
was demonstrated to have desired type one error rates. Moreover, the statistical power for 
the proposed design was comparable to traditional design with a significant reeducation on 
genotyping cost. Finally, optimal designs to detect functioning rare allele under different 
scenarios were given.  
Conclusively, we proposed different statistical methods to investigate drug 
responses. The metabolism of drugs in human system is a sophisticated process. The 
individual variability to drug response can be caused by many factors, especially for DDIs. 
Many of such individual variability can be explained by pharmacokinetics and 
pharmacodynamics, in which genomics is heavily involved. However, many ADEs can 
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only be identified through large-scale population based pharmacovigilance studies. 
Significant drug-ADE associations detected from pharmacovigilance studies post warnings 
for future prescriptions. Those result can also serve as primary outcomes for 
pharmacogenomics studies, in which the mechanism of the drug-ADE association can be 
explored. If predictive genetic markers can be found, it can be used to prevent or minimize 
adverse drug reactions in vulnerable populations. 
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Appendix A. Supplemental Materials for Chapter 2 
A.1.  The properties of the top-ranked signals for the methods in section 2.2 
Each method has its own properties on signal ranking and generation. We evaluated 
such properties through simulation studies (for data generation, please visit section 2.4.1). 
We examined the average report frequency and observed relative risks (RRs) for each of 
the top-200 ranked signals by the signal detection methods in section 2.2.  
Top-ranked signals by different methods have different magnitudes on the report 
frequencies and observed relative risks. Top-ranked signals of LRT and BFDR have the 
largest magnitude on the report frequencies and moderate observed relative risks (RRs). 
Top-ranked signals of IC and lFDR have smaller magnitude on the report frequencies 
compared to LRT and BFDR. While, they have greater magnitude on the observed RRs. 
Compared with top-ranked signals of IC and lFDR, EBGM top-ranked signals have a 
similar magnitude on observed RR, but a smaller magnitude on the observed report 
frequencies. Finally, PRR based ranking is most likely to be influenced by sampling 
variation, as its top-ranked signals have extremely low report frequencies. The average 
report frequencies for top-200 ranked signals by different methods are shown in figure A.1. 
The average observed RRs for top-200 ranked signals by different methods are shown in 
figure A.2. 
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Figure A.1. Log-average-outcome of top-200 ranked signals by different methods 
 
Figure A.2. Observed RR of top-200 ranked signals by different methods 
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A.2.   The properties of signal generations by the methods in section 2.2 
We also examine four commonly adopted signal generation rules with respect to 
the percentage of background noises among generated signals. These rules are EB05>2, 
IC025>0, PRR025>1 and lFDR<0.05. We notice that these rules are not comparable to 
each other. For instance, EB05>2 is a stronger rule compared with PRR025>1 and IC025>0. 
The primary aim for this investigation is to understand the performance for these methods. 
These knowledges can be used to serve as reference for future pharmacovigilance studies. 
For simulation 𝑖, we define the false positive rate (FPR𝑖) to be 
FPR𝑖 =
# of Signals generated by noise (𝛿𝑖𝑗 = 2) 
# of Signals
. 
The evaluation will be based on the average of FPR𝑖s, FPR = AVE(FPR𝑖), from 1,000 
simulations.  
In order to understand each signal detection rule in a detailed level, we partition the 
simulated report data into groups based on their report frequencies and observed RRs. Then, 
the empirical FPRs within each subgroup will be calculated and examined (figure A.3). As 
figure A.3 shown, lFDR<0.05 is the only method that successfully controlled the FPRs at 
the desired level. As we expected, EBGM>2 is a stronger rule and generates no signal for 
those observations with observed RR<2. Additionally, lFDR<0.05 generates no signal for 
those observations with observed RR<3.  
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A.3. Supplemental figures and tables 
Figure A.4: Comparison between the of observed RRs to the EBGMs estimated 
from the proposed three-component EBMM (EBGM_3), for those drug-ADE 
combinations with their observed RR less than 100. 
Figure A.5: Estimated density functions of positive RR and their mixture. 
Figure A.6: A histogram of estimated lFDRs. We observed that most drug-ADE 
pairs to have their lFDRs around one. A small peak around 0 indicates signals.   
Table A.1: A list of the ADEs and their risks in the four ADE data. 
Table A.2: Top drug-ADE associations in the four ADE data. 
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Figure A.4. Comparison of ?̂? to the EBGM_3s (?̂? < 100) 
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Figure A.5. Density plot of lambdas 
 
 
Figure A.6. Distribution of estimated lFDR 
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Table A.1. Frequency table of outcomes by all ADEs 
ADE Name Frequency 
MYALGIA 0.1394 
MUSCULAR WEAKNESS 0.1117 
NEUROPATHY PERIPHERAL 0.1099 
RHABDOMYOLYSIS 0.0618 
LYMPHADENOPATHY 0.0563 
LIVER FUNCTION TEST ABNORMAL 0.0538 
HEPATIC FUNCTION ABNORMAL 0.0469 
HEPATIC FAILURE 0.0435 
JAUNDICE 0.0407 
LUNG INFILTRATION 0.0369 
DELIRIUM 0.036 
HEPATOMEGALY 0.022 
CHOLESTASIS 0.0208 
DIABETIC NEUROPATHY 0.0206 
SPLENOMEGALY 0.0187 
HEPATIC CIRRHOSIS 0.0173 
HYPERBILIRUBINAEMIA 0.0129 
HEPATIC ENCEPHALOPATHY 0.0128 
MYOSITIS 0.0126 
POLYNEUROPATHY 0.0119 
HEPATOCELLULAR INJURY 0.0118 
SKIN HYPERPIGMENTATION 0.0111 
ACUTE HEPATIC FAILURE 0.0089 
HEPATITIS CHOLESTATIC 0.0077 
HEPATIC NECROSIS 0.0074 
OCULAR ICTERUS 0.0062 
PERIPHERAL SENSORY NEUROPATHY 0.0061 
JAUNDICE CHOLESTATIC 0.0059 
PIGMENTATION DISORDER 0.0047 
OPTIC ISCHAEMIC NEUROPATHY 0.0036 
HEPATORENAL SYNDROME 0.0033 
YELLOW SKIN 0.0032 
AUTONOMIC NEUROPATHY 0.0023 
POLYMYOSITIS 0.0022 
ASTERIXIS 0.0021 
GRANULOMATOUS LIVER DISEASE 0.0021 
OPTIC NEUROPATHY 0.002 
PERIPHERAL MOTOR NEUROPATHY 0.002 
DEMYELINATING POLYNEUROPATHY 0.0018 
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COMA HEPATIC 0.0015 
PERIPHERAL SENSORIMOTOR NEUROPATHY 0.0015 
MYOGLOBINURIA 0.0013 
BIOPSY LIVER ABNORMAL 0.0012 
AXONAL NEUROPATHY 0.001 
CHRONIC HEPATIC FAILURE 0.001 
SKIN HYPOPIGMENTATION 0.001 
CORNEAL OPACITY <0.001 
HEPATORENAL FAILURE <0.001 
SKIN DEPIGMENTATION <0.001 
CORNEAL DEPOSITS <0.001 
MONONEUROPATHY MULTIPLEX <0.001 
CHRONIC INFLAMMATORY DEMYELINATING 
POLYRADICULONEUROPATHY <0.001 
POST CHOLECYSTECTOMY SYNDROME <0.001 
CHOLESTASIS OF PREGNANCY <0.001 
MONONEUROPATHY <0.001 
HYPERBILIRUBINAEMIA NEONATAL <0.001 
MACROPHAGES INCREASED <0.001 
CRITICAL ILLNESS POLYNEUROPATHY <0.001 
DIABETIC AUTONOMIC NEUROPATHY <0.001 
SENSORY NEUROPATHY HEREDITARY <0.001 
TOXIC NEUROPATHY <0.001 
ACUTE POLYNEUROPATHY <0.001 
ISCHAEMIC NEUROPATHY <0.001 
POLYNEUROPATHY IDIOPATHIC PROGRESSIVE <0.001 
RADIATION NEUROPATHY <0.001 
SCIATIC NERVE NEUROPATHY <0.001 
SUBACUTE HEPATIC FAILURE <0.001 
TOXIC OPTIC NEUROPATHY <0.001 
DEFICIENCY OF BILE SECRETION <0.001 
FATTY LIVER ALCOHOLIC <0.001 
HISTIOCYTOSIS <0.001 
JAUNDICE ACHOLURIC <0.001 
LIPIDOSIS <0.001 
NEONATAL CHOLESTASIS <0.001 
POLYNEUROPATHY IN MALIGNANT DISEASE <0.001 
AUTOIMMUNE NEUROPATHY <0.001 
CARDIAC AUTONOMIC NEUROPATHY <0.001 
CONGENITAL NEUROPATHY <0.001 
DIABETIC MONONEUROPATHY <0.001 
HIV PERIPHERAL NEUROPATHY <0.001 
JAUNDICE EXTRAHEPATIC OBSTRUCTIVE <0.001 
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KERNICTERUS <0.001 
LUNG INFILTRATION MALIGNANT <0.001 
MULTIFOCAL MOTOR NEUROPATHY <0.001 
PHAGOCYTOSIS <0.001 
POLYNEUROPATHY ALCOHOLIC <0.001 
POLYNEUROPATHY CHRONIC <0.001 
NEURONAL NEUROPATHY <0.001 
HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE 
PALSIES <0.001 
LUPOID HEPATIC CIRRHOSIS <0.001 
MACROPHAGES DECREASED <0.001 
MITOCHONDRIAL HEPATOPATHY <0.001 
OBTURATOR NEUROPATHY <0.001 
URAEMIC NEUROPATHY <0.001 
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Appendix B. Derivations for section 4.2 
B.1.  Properties of minor allele frequency (MAF) within a DNA pool 
Without pooling variation, the percentage of DNA contributed by each subject in a 
pool will be exactly 
1
𝑆𝑃
 for a pool of 𝑆𝑃 samples. In order to adjust for pooling variation, 
the individual contributions in a DNA pool are assumed to follow a Dirichlet distribution 
such that 𝑫~𝐷𝑖𝑟(𝑆𝑃, 𝜅). The properties of this Dirichlet distribution are 𝐸  (𝐷𝑖) =
1
𝑆𝑃
 , 
𝑉𝐴𝑅(𝐷𝑖) =
𝑆𝑃−1
𝑆𝑃
2(𝜅𝑆𝑃+1)
 and 𝐶𝑂𝑉(𝐷𝑖 , 𝐷𝑗) =
−1
𝑆𝑃
2(𝜅𝑆𝑃+1)
 for 𝑖 ≠ 𝑗 . Then the minor allele 
frequency (MAF) within a particular DNA pool is 𝑣 = ∑
𝑔𝑖𝑑𝑖
2
 𝑆𝑃𝑖  (∑ 𝑑𝑖
𝑆𝑃
𝑖=1 = 1). Denoting 
the underlining MAF to be 𝑞, the expectation and variance of 𝜐 can be derived as: 
𝐸(𝑣) = 𝐸 (∑
𝑔𝑖𝑑𝑖
2
𝑆𝑃
𝑖
) = ∑[𝐸 (
𝑔𝑖
2
)𝐸(𝑑𝑖)]
𝑆𝑃
𝑖
= 𝑞. (B.1) 
 
𝑉𝐴𝑅(𝑣) = 𝐸 [(∑
𝑔𝑖𝑑𝑖
2
𝑆𝑃
𝑖
)
2
] − [𝐸 (∑
𝑔𝑖𝑑𝑖
2
𝑆𝑃
𝑖
)]
2
 
 
= 𝐸 [
1
4
∑∑(𝑔𝑖𝑑𝑖 × 𝑔𝑗𝑑𝑗)
𝑆𝑃
𝑗
𝑆𝑃
𝑖
] − 𝑞2 
 
= 𝐸𝑫 [
1
4
∑∑𝐸𝑮(𝑔𝑖𝑔𝑗)𝑑𝑖𝑑𝑗
𝑆𝑃
𝑗
𝑆𝑃
𝑖
] − 𝑞2 
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= 𝐸𝑫 [
𝑞(1 − 𝑞)
2
∑𝑑𝑖
2
𝑆𝑃
𝑖
+ 𝑞2 ∑∑𝑑𝑖𝑑𝑗
𝑆𝑃
𝑗
𝑆𝑃
𝑖
] − 𝑞2 
 
= 𝐸𝑫 [
𝑞(1 − 𝑞)
2
∑𝑑𝑖
2
𝑆𝑃
𝑖
] =
𝑞(1 − 𝑞)
2𝑆𝑃
[1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
]. (B.2) 
In deriving (B.2), we use the fact that ∑ ∑ 𝑑𝑖𝑑𝑗
𝑆𝑃
𝑗
𝑆𝑃
𝑖 = 1. Additionally, 𝐸𝑫 refers to taking 
expectation with respect to individual contribution and 𝐸𝑮 refers to taking expectation with 
respect to genotype. Such a notation for the expectations will be used throughout this 
appendix. Thus, the ratio of pooling variation to sampling variation can be characterized 
by 
𝑆𝑃−1
𝜅𝑆𝑃+1
. 
 
B.2. Properties of sequencing outcome 
The joint distribution of sequencing reads 𝑅 and its mean 𝜆 is 
𝑓(𝑅, 𝜆) = (
𝜆𝑅
𝑅!
𝑒−𝜆) ×
𝛽𝛼
Γ(𝛼)
𝜆𝛼−1𝑒−𝛽𝜆. 
By integrating out the 𝜆, the observed distribution of 𝑅  is a negative binomial 
distribution 
 
𝑓(𝑟) =
Γ(𝛼 + 𝑟)
𝑟! Γ(𝛼)
(
𝛽
1 + 𝛽
)
𝛼
(
1
1 + 𝛽
)
𝑟
. 
 
The expectation of R is 𝐸(𝑅) =
𝛼
𝛽
. The second and third central moments of 𝑅  are 
𝐸 (𝑅 −
𝛼
𝛽
)
2
=
𝛼(1+𝛽)
𝛽2
 and 𝐸 (𝑅 −
𝛼
𝛽
)
3
=
𝛼(1+𝛽)(2+𝛽)
𝛽3
. The estimation of MAF involves the 
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reciprocal of 𝑅. Its expectation, 𝐸 (
𝐼(𝑅≠0)
𝑅
), can be approximate by Taylor expansion as 
shown in equation (B.3): 
 
𝐼(𝑅 ≠ 0)
𝑅
=
1
𝐸(𝑅)
−
𝑅 −
𝛼
𝛽
[𝐸(𝑅)]2
+
(𝑅 −
𝛼
𝛽)
2
[𝐸(𝑅)]3
−
(𝑅 −
𝛼
𝛽)
3
[𝐸(𝑅)]4
+ ⋯ 
(B.3) 
For enough sequencing depth, 𝐸 (
𝐼(𝑅≠0)
𝑅
) ≈
𝛼𝛽+𝛽2+1
𝛼2
+ 𝜊 (
𝛽
𝛼
)
2
.  
For a single read in a particular genetic pool, with sequencing error, 𝐼(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑟𝑒𝑎𝑑𝑠 =
𝑎) is a binary random variable. Its expectation and variance is 
𝐸[𝐼(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑟𝑒𝑎𝑑𝑠 = 𝑎)] = 𝜐(1 − 𝜔𝑎) + (1 − 𝜐)𝜔𝐴 = 𝓋 and 
𝑉𝐴𝑅[𝐼(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑟𝑒𝑎𝑑𝑠 = 𝑎)] = 𝓋(1 − 𝓋). 
(B.4) 
From (B.1) and (B.2), we have 
𝐸(𝓋) = 𝑞(1 − 𝜔𝐴 − 𝜔𝑎) + 𝜔𝐴 and 
(B.5) 
𝑉𝐴𝑅(𝓋) = (1 − 𝜔𝐴 − 𝜔𝑎)
2 ×
𝑞(1−𝑞)
2𝑆𝑃
× [1 +
𝑆𝑃−1
𝜅𝑆𝑃+1
]. 
 
B.3. Derivations in section 4.2.3  
B.3.1. Derivation of equation (4.2) 
We assume the two alleles carried by each subject (one inherit from father and the 
other from mother) are independent with each other. Denote the allele type as 𝐿 =
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𝐼(𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎). Let 𝐿1 and 𝐿2 represent indicator variables for the two alleles carried by 
each individual. 𝜋1 can be derived as 
𝑃[𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎|𝑌 = 1] =
𝑃(𝑎𝑙𝑙𝑒𝑙𝑒 = 𝑎, 𝑌 = 1)
𝑃(𝑌 = 1)
 
 
=
𝑃(𝑎𝑙𝑙𝑒𝑙𝑒1 = 𝑎, 𝑎𝑙𝑙𝑒𝑙𝑒2 = 𝑎, 𝑌 = 1)
𝑃(𝑌 = 1)
 
           +
𝑃(𝑎𝑙𝑙𝑒𝑙𝑒1 = 𝑎, 𝑎𝑙𝑙𝑒𝑙𝑒2 = 𝐴, 𝑌 = 1)
𝑃(𝑌 = 1)
 
 
=
𝑃(𝑌 = 1|𝐿1 = 1, 𝐿2 = 1)𝑃(𝐿1 = 1, 𝐿2 = 1)
∑ 𝑃(𝑌 = 1|𝐺 = 𝑖)𝑃(𝐺 = 𝑖)2𝑖=0
 
           +
𝑃(𝑌 = 1|𝐿1 = 1, 𝐿2 = 0)𝑃(𝐿1 = 1, 𝐿2 = 0)
∑ 𝑃(𝑌 = 1|𝐺 = 𝑖)𝑃(𝐺 = 𝑖)2𝑖=0
 
 
=
(𝑌 = 1|𝐺 = 2)𝑃(𝐺 = 2) +
1
2 (𝑌 = 1|𝐺 = 1)𝑃(𝐺 = 1)
∑ 𝑃(𝑌 = 1|𝐺 = 𝑖)𝑃(𝐺 = 𝑖)2𝑖=0
. 
Similarly, 𝜋0 can be derived. 
 
B.3.2. Derivation of equation (4.4) 
Assuming 𝑁1
∗ ≠ 0 or 𝑁∗, equation (4.4) can be written as: 
 
𝐸(?̃?1
∗ − ?̃?0
∗) = 𝐸𝒀∗ [𝐸 (
∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
𝑁𝑃1
∗ | 𝒀
∗)] − 𝐸𝒀∗ [𝐸 (
∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
𝑁𝑃0
∗ | 𝒀
∗)]. (B.6) 
Where in (B.6), 
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𝐸 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
) = 𝐸𝑹∗,𝒗𝟏∗ [𝐸 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
| 𝑹∗, 𝒗𝟏
∗)]  
 = ∑ 𝐸[𝑣1,𝑖
∗ (1 − 𝜔𝑎) + (1 − 𝑣1,𝑖
∗ )𝜔𝐴]
𝑁𝑃1
∗
𝑖=1
 
 
 = 𝑁𝑃1
∗ [𝜋1(1 − 𝜔𝐴 − 𝜔𝑎) + 𝜔𝐴]. (B.7) 
 
𝐸 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
) = 𝐸𝑹∗,𝒗𝟎∗ [𝐸 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
| 𝑹∗, 𝒗𝟎
∗)]  
 = ∑ 𝐸[𝑣0,𝑖
∗ (1 − 𝜔𝑎) + (1 − 𝑣0,𝑖
∗ )𝜔𝐴]
𝑁𝑃0
∗
𝑖=1
 
 
 = 𝑁𝑃0
∗ [𝜋0(1 − 𝜔𝐴 − 𝜔𝑎) + 𝜔𝐴]. (B.8) 
Thus, 𝐸(?̃?1
∗ − ?̃?0
∗) = (𝜋1 − 𝜋0) × (1 − 𝜔𝐴 − 𝜔𝑎). 
 
B.3.3. Derivation of equation (4.5) 
Assuming 𝑁1
∗ ≠ 0 or 𝑁∗, equation (4.5) can be written as: 
𝑉𝐴𝑅( ?̃?1
∗ − ?̃?0
∗) = 𝐸𝒀∗
[
 
 
 
 
𝑉𝐴𝑅
(
 
 
∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
𝑁𝑃1
∗ −
∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
𝑁𝑃0
∗ || 𝒀
∗
)
 
 
]
 
 
 
 
+ 𝑉𝐴𝑅𝒀∗
[
 
 
 
 
𝐸
(
 
 
∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
𝑁𝑃1
∗ −
∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
𝑁𝑃0
∗ || 𝒀
∗
)
 
 
]
 
 
 
 
 
 
= 𝐸𝒀∗
[
 
 
 𝑉𝐴𝑅 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1 )
(𝑁𝑃1
∗ )2
+
𝑉𝐴𝑅 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1 )
(𝑁𝑃0
∗ )2
]
 
 
 
+ 𝑉𝐴𝑅𝒀∗
[
 
 
 𝐸 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1 )
𝑁𝑃1
∗ −
𝐸 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1 )
𝑁𝑃0
∗
]
 
 
 
. 
(B.9) 
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Recall that 𝓋∗ = 𝑣∗(1 − 𝜔𝑎) + (1 − 𝑣
∗)𝜔𝐴 and 𝐸 (
𝐼(𝑅≠0)
𝑅
) ≈
𝛼𝛽+𝛽2+1
𝛼2
. Let 𝜛 =
𝛼𝛽+𝛽2+1
𝛼2
, 
𝑉𝐴𝑅 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1 ) can be derived as: 
𝑉𝐴𝑅 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
) = 𝐸𝑹∗,𝒗𝟏
∗ [𝑉𝐴𝑅 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
| 𝑹∗, 𝒗𝟏
∗)] + 𝑉𝐴𝑅𝑹∗,𝒗𝟏
∗ [𝐸 (∑
𝐶1,𝑖
∗
𝑅1𝑖,
∗
𝑁𝑃1
∗
𝑖=1
| 𝑹∗, 𝒗𝟏
∗)] 
 
= 𝐸𝑹∗,𝒗𝟏
∗ [∑
𝓋1,𝑖
∗ (1 − 𝓋1,𝑖
∗ )
𝑅1𝑖
∗
𝑁𝑃1
∗
𝑖=1
] + 𝑉𝐴𝑅𝒗𝟏
∗ (∑ 𝓋1,𝑖
∗
𝑁𝑃1
∗
𝑖=1
) 
 
≈ ∑ [
𝐸(𝓋1,𝑖
∗ ) − 𝑉𝐴𝑅(𝓋1,𝑖
∗ ) − 𝐸2(𝓋1,𝑖
∗ )
𝜛−1
+ 𝑉𝐴𝑅(𝓋1,𝑖
∗ )]
𝑁𝑃1
∗
𝑖=1
 
 
= ∑ [
𝐸(𝓋1,𝑖
∗ ) − 𝐸2(𝓋1,𝑖
∗ )
𝜛−1
+ (1 − 𝜛) × 𝑉𝐴𝑅(𝓋1,𝑖
∗ )]
𝑁𝑃1
∗
𝑖=1
 
 
= 𝑁𝑃1
∗ × {
[𝜔𝐴 + 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)]
𝜛−1
+ (1 − 𝜛)
× (1 − 𝜔𝐴 − 𝜔𝑎)
2 ×
𝜋1(1 − 𝜋1)
2𝑆𝑃
× (1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
)}. 
(B.10) 
Similarly 
𝑉𝐴𝑅 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1
) ≈ 𝑁𝑃0
∗ × {
[𝜔𝐴 + 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)]
𝜛−1
+ (1 − 𝜛) × (1 − 𝜔𝐴 − 𝜔𝑎)
2 ×
𝜋0(1 − 𝜋0)
2𝑆𝑃
× (1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
)}. 
(B.11) 
(B.7) and (B.8) imply  
 
𝑉𝐴𝑅𝒀∗ [
𝐸(∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1 )
𝑁𝑃1
∗ −
𝐸(∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1 )
𝑁𝑃0
∗ ] = 𝑉𝐴𝑅𝒀∗[(𝜋1 − 𝜋0) × (1 − 𝜔1 − 𝜔2)] = 0. (B.12) 
Similarly as (B.3), the expectation of 
1
𝑁1
∗ and 
1
𝑁0
∗ can be obtained as: 
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 𝐸 (
𝐼(𝑁1
∗≠0)
𝑁1
∗ ) ≈
1
𝑁∗𝜋𝐷
+ 𝜊 (
1
𝑁∗𝜋𝐷
) and 𝐸 (
𝐼(𝑁0
∗≠0)
𝑁0
∗ ) ≈
1
𝑁∗(1−𝜋𝐷)
+ 𝜊 (
1
𝑁∗(1−𝜋𝐷)
). (B.13) 
(B.10) to (B.13) together imply 
𝑉𝐴𝑅(?̃?1
∗ − ?̃?0
∗) = 𝐸𝒀∗
[
 
 
 𝑉𝐴𝑅 (∑
𝐶1,𝑖
∗
𝑅1,𝑖
∗
𝑁𝑃1
∗
𝑖=1 )
(𝑁𝑃1
∗ )2
+
𝑉𝐴𝑅 (∑
𝐶0,𝑖
∗
𝑅0,𝑖
∗
𝑁𝑃0
∗
𝑖=1 )
(𝑁𝑃0
∗ )2
]
 
 
 
 
 ≈ [(1 − 𝜛) × (1 − 𝜔𝐴 − 𝜔𝑎)
2 (1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
)] × 𝐸𝒀∗ [
𝜋1(1 − 𝜋1)
2𝑆𝑃 × 𝑁𝑃1
∗ +
𝜋0(1 − 𝜋0)
2𝑆𝑃 × 𝑁𝑃0
∗ ] 
 
+𝜛 × 𝐸𝒀∗ {
[𝜔𝐴 + 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)]
𝑁𝑃1
∗
+
[𝜔𝐴 + 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)]
𝑁𝑃0
∗ } 
≈ [(1 − 𝜛) × (1 − 𝜔𝐴 − 𝜔𝑎)
2 × (1 +
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
)] × [
𝜋1(1 − 𝜋1)
2𝑁∗𝜋𝐷
+
𝜋0(1 − 𝜋0)
2𝑁∗(1 − 𝜋𝐷)
] 
+2𝑆𝑝𝑜𝑜𝑙 × 𝜛 × {
[𝜔𝐴 + 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋1(1 − 𝜔𝐴 − 𝜔𝑎)]
2𝑁∗𝜋𝐷
+
[𝜔𝐴 + 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)][1 − 𝜔𝐴 − 𝜋0(1 − 𝜔𝐴 − 𝜔𝑎)]
2𝑁∗(1 − 𝜋𝐷)
}. 
(B.14) 
Without the presentence of sequencing error (𝜔𝐴 = 𝜔𝑎 = 0), (S1.14) can be simplified as  
 
𝑉𝐴𝑅(?̃?1
∗ − ?̃?0
∗) = [1 + 𝜛(2𝑆𝑝𝑜𝑜𝑙 − 1) + (1 − 𝜛) ×
𝑆𝑃 − 1
𝜅𝑆𝑃 + 1
]
× [
𝜋1(1 − 𝜋1)
2𝑁∗𝜋𝐷
+
𝜋0(1 − 𝜋0)
2𝑁∗(1 − 𝜋𝐷)
]. 
(B.15) 
The variations induced by sequencing and DNA pooling can be reduced by either 
increasing sequencing depth (𝜛 =
𝛼𝛽+𝛽2+1
𝛼2
→ 0)  or carefully conducting DNA pools 
(
𝑆𝑃−1
𝜅𝑆𝑃+1
→ 0).  
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B.3.4. Derivation of equation (4.9) 
Recall that 𝜋1 = 𝑃(𝐿 = 1|𝑌 = 1), 𝜋0 = 𝑃(𝐿 = 1|𝑌 = 0) and 𝜋𝐷 = 𝑃(𝑌 = 1). 
Let 𝐿1 and 𝐿2 be defined same as in section B.3.1. The observed likelihood of 𝑔𝑖
∗s and 
𝑦𝑖
∗s can be written as 
 
Lik = ∏{[𝜋1
𝑙1,𝑖
∗ +𝑙2,𝑖
∗
(1 − 𝜋1)
2−𝑙1,𝑖
∗ −𝑙2,𝑖
∗
𝜋𝐷]
𝑦𝑖
∗
[𝜋0
𝑙1,𝑖
∗ +𝑙2,𝑖
∗
(1 − 𝜋0)
2−𝑙1,𝑖
∗ −𝑙2,𝑖
∗
(1
𝑁∗
𝑖=1
− 𝜋𝐷)]
1−𝑦𝑖
∗
}
= {𝜋1
∑𝑔𝑖
∗𝑦𝑖
∗
(1 − 𝜋1)
2∑𝑦𝑖
∗−∑𝑔𝑖
∗𝑦𝑖
∗
} {𝜋0
∑𝑔𝑖
∗−∑𝑔𝑖
∗𝑦𝑖
∗
(1
− 𝜋0)
2𝑁∗−2∑𝑦𝑖
∗−∑𝑔𝑖
∗+∑𝑔𝑖
∗𝑦𝑖
∗
} {𝜋𝐷
∑𝑦𝑖
∗
(1 − 𝜋𝐷)
𝑁∗−∑𝑦𝑖
∗
}. 
 
And the log-likelihood can be written as 
 llik = [∑𝑔𝑖
∗𝑦𝑖
∗ log 𝜋1 + (2∑ 𝑦𝑖
∗ − ∑ 𝑔𝑖
∗𝑦𝑖
∗) log(1 − 𝜋1)]
+ [(∑𝑔𝑖
∗ − ∑𝑔𝑖
∗𝑦𝑖
∗) log 𝜋0
+ (2𝑁∗ − 2∑𝑦𝑖
∗ − ∑𝑔𝑖
∗ + ∑𝑔𝑖
∗𝑦𝑖
∗) log(1 − 𝜋0)]
+ [∑𝑦𝑖
∗ log 𝜋𝐷 + (𝑁
∗ − ∑ 𝑦𝑖
∗) log(1 − 𝜋𝐷)]. 
(B.16) 
Hence ?̂?1
∗ =
∑ 𝑔1,𝑖
∗𝑁1
∗
𝑖=1
2𝑁1
∗  and ?̂?0
∗ =
∑ 𝑔0,𝑖
∗𝑁0
∗
𝑖=1
2𝑁0
∗ .  
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B.3.5. Derivation of equation (4.11) 
Let 𝑮∗ be the 𝑁∗ by 2 design matrix of intercept and genotype 𝐺 for the first stage 
and 𝒁 be the 𝑁 by 2 design matrix of intercept and covariate 𝑍. Both ?̂?𝛿
∗  and ?̂?1 can be 
written as a function of 𝒀 such that 
 
?̂?𝛿
∗ =
∑𝑔𝑖
∗𝑦𝑖
∗
2∑𝑦𝑖
∗ −
∑𝑔𝑖
∗−∑𝑔𝑖
∗𝑦𝑖
∗
2𝑁∗−2∑𝑦𝑖
∗ = 𝑓 (
𝑮∗
𝑇
𝒀∗
𝑁∗
) and 
(B.17) 
 (?̂? − 𝜷𝑇) = 𝐼
−1(𝜷𝑆)𝒁
𝑇[𝒀 − 𝐸(𝒀)]. 
In (B.17), 𝒁𝑇[𝒀 − 𝐸(𝒀)] is the score function, 𝐼−1(𝜷) is the Hessian matrix for logistic 
model (7), 𝜷𝑇 is the true parameter and 𝜷𝑆 lines in between the line segment of ?̂? and 𝜷𝑇. 
It is well established that 
𝑮∗
𝑇
𝒀∗
𝑁∗
 is consistent estimator of [
2𝜋1𝜋𝐷
𝜋𝐷
] and ?̂?1  is consistent 
estimator of 𝛽1. Their asymptotic joint normality follows from multivariate central limit 
theorem. The theoretical covariance of 
𝑮∗
𝑇
𝒀∗
𝑁∗
 and ?̂?1 is 
 𝐶𝑂𝑉 (
𝑮∗𝑇𝒀∗
𝑁∗
 , ?̂?1) =
1
𝑁
× [
0
−𝐸[𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)] + 𝐸[𝑍𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑉𝐴𝑅(𝑌)]
𝐸[𝑉𝐴𝑅(𝑌)]𝐸[𝑍2 × 𝑉𝐴𝑅(𝑌)] − {𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)]}2
] (B.18) 
From (B.19), the theoretical covariance between ?̂?𝛿
∗  and ?̂? can be calculated via delta 
method. By taking the partial derivatives of 𝑓 ([
2𝜋1𝜋𝐷
𝜋𝐷
]) and plug in 
𝑮∗
𝑇
𝒀∗
𝑁∗
, we have 
 
𝐶𝑂𝑉(?̂?𝛿
∗  , ?̂?1) =
−𝐸[𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)] + 𝐸[𝑍𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑉𝐴𝑅(𝑌)]
𝐸[𝑉𝐴𝑅(𝑌)]𝐸[𝑍2 × 𝑉𝐴𝑅(𝑌)] − {𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)]}2
2𝑁 × 𝑉𝐴𝑅(𝑌)
. 
(B.19) 
Similarly, the variance of ?̂?𝛿
∗  can be obtained by delta method.  
 122 
 
 
𝑉𝐴𝑅(?̂?𝛿
∗  ) = (
1
2√𝑁∗ × 𝑉𝐴𝑅(𝑌)
)
2
{𝑘2 × 𝐸[𝑉𝐴𝑅(𝑌)] − 2𝑘 × 𝐸[𝐺 × 𝑉𝐴𝑅(𝑌)]
+ 𝐸[𝐺2 × 𝑉𝐴𝑅(𝑌)]}. 
(B.20) 
Where in (B.20), 𝑘 =
𝐶𝑂𝑉(𝐺,𝑌)×[1−2𝐸(𝑌)]
𝑉𝐴𝑅(𝑌)
+ 𝐸(𝐺). Finally, the theoretical variances ?̂?1 is 
 𝑉𝐴𝑅(?̂?1) =
1
𝑁
𝐸[𝑉𝐴𝑅(𝑌)]
𝐸[𝑉𝐴𝑅(𝑌)]𝐸[𝑍2×𝑉𝐴𝑅(𝑌)]−{𝐸[𝑍×𝑉𝐴𝑅(𝑌)]}2
. (B.21) 
(B.19) - (B.21) together implies  
𝜌 =
√𝑁∗
√𝑁
×
−𝐸[𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)] + 𝐸[𝑍𝐺 × 𝑉𝐴𝑅(𝑌)]𝐸[𝑉𝐴𝑅(𝑌)]
√𝐸[𝑉𝐴𝑅(𝑌)]𝐸[𝑍2 × 𝑉𝐴𝑅(𝑌)] − {𝐸[𝑍 × 𝑉𝐴𝑅(𝑌)]}2
√𝐸[𝑉𝐴𝑅(𝑌)]{𝑘2 × 𝐸[𝑉𝐴𝑅(𝑌)] − 2𝑘 × 𝐸[𝐺 × 𝑉𝐴𝑅(𝑌)] + 𝐸[𝐺2 × 𝑉𝐴𝑅(𝑌)]}
. 
(B.22) 
Under null hypothesis, 𝑌 and 𝐺 are independent. Hence, the correlation can be simplified 
as 𝜌 =
√𝑁∗
√𝑁
𝐶𝑂𝑅(𝐺, 𝑍). 
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Appendix C. Cost for Genotyping 
In this section, genotyping costs for pharmacogenomics studies will be discussed 
and summarized. The exact genotyping cost is affected by many factors. Here, we only 
consider two major source of cost: experiment cost and genotyping cost. Additionally, both 
experiment cost and genotyping cost depends on the design of the experiment. All the cost 
are in US dollars.  
C.1.  Experimental cost 
Besides the cost of genotyping, the cost for a pharmacogenomics study may include 
but not limited to the following: DNA acquiring, DNA processing, DNA capture, sample 
QC and library preparation. Such cost are typically depends on the genotyping procedure. 
For instance, DNA capture are required for targeted genome sequencing only. For whole 
genome sequencing, standard cost for a sample is $250 or higher. For targeted sequencing 
or whole exome sequencing, the cost to prepare a sample will be increased due to DNA 
capture. For a population based study, DNA pooling will reduce not only genotyping cost 
but also experiment cost. 
C.2.  Genotyping cost by sequencing 
In this section, we consider the costs and throughputs for Illumina DNA sequencing 
platforms. The cost of DNA sequencing associated with the sequencing depth, the length 
of genome to be sequenced, and number of libraries. The production of these three 
parameters determined the expected cost for DNA sequencing. The internal prices of 
sequencing services offered by four different universities are summarized in table C.1. The 
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external prices are expected to be 30%-100% higher. In table C.1, 1x denotes single end 
(SE) and 2x denotes pair ends (PE). 
Table C.1. Internal prices in U.S. dollars for sequencing services offered from UT 
Austina, Wisconsin University b, Cornell Universityc and Rockefeller Universityd 
Platform 
Throughput 
(Reads) 
Read length 
(Base pair) 
Price 
(Per lane/run) 
Hiseq 4000 240M/lane 1x100 $1,319 
Hiseq 2500 200M/lane 2x125 $2,500 
Nextseq 500 330M/run 1x150 $3,000 
Miseq V2 15M/lane 2x250 $1625 
Miseq V3 25M/lane 2x300 $2175 
ahttps://wikis.utexas.edu/display/GSAF/Pricing 
bhttps://www.biotech.wisc.edu/services/dnaseq/sequencing/Illumina 
chttp://www.biotech.cornell.edu/brc/genomics/services/price-list 
dhttp://www.rockefeller.edu/genomics/pricing 
 
Note that the choice of sequencing platform is usually driven by the experiment. For 
instance, Miseq platforms are not designed to sequence large genome. 
3.  Genotyping cost by SNP array 
DNA sequencing is powerful to detect rare alleles, while SNP array is a well-established 
technology to test SNP variants. Currently, OpenArray and GoldenGate are two leading 
customizable chips for SNP genotyping. SNP genotyping has to adopt the chip format 
designed by the manufacturer. The cost for genotyping by SNP array are usually measured 
by cost per probe (SNP). Table C.2 illustrated the format and cost for OpenArray’s chip. 
The total cost for genotyping by SNP array are made up of an initial cost, chip cost and 
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reagent cost. As the number of SNPs to be tested increases, the cost per SNP will be 
decreased. Thus, the cost per probe ranged from $0.15 to $1. Quotes of SNP genotyping 
can be find at Harvard University (http://www.hsph.harvard.edu/program-molecular-
genetic-epidemiology/genotyping-core-facility/) and University of Pennsylvania 
(https://somapps.med.upenn.edu/pbr/portal/mpf/fees.php). 
Table C.2. OpenArray’s chip format with expected costs 
Chip Format # Samples/Chip 
Minimum # of 
Chips 
Total cost 
Cost per 
probe 
16 SNPs 144 10 (1440) $6,975 0.30 
32 SNPs 96 10 (960) $6,945 0.22 
64 SNPs 48 20 (960) $13,525 0.22 
128 SNPs 24 40 (960) $26,850 0.22 
192 SNPs 16 60 (960) $40,175 0.22 
256 SNPs 12 80 (960) $49,500 0.20 
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